Bipolar off-wall electrode device for renal nerve ablation

Information

  • Patent Grant
  • 9649156
  • Patent Number
    9,649,156
  • Date Filed
    Thursday, February 12, 2015
    9 years ago
  • Date Issued
    Tuesday, May 16, 2017
    7 years ago
Abstract
A first spacing structure is provided at a distal end of a first catheter. The first spacing structure is configured to position at least one arterial electrode at a predefined distance away from a wall of the renal artery. A second spacing structure is provided at the distal end of the first catheter or at a distal end of a second catheter. The second spacing structure is configured to position at least one aortal electrode at a predefined distance away from a wall of the aorta. The arterial and aortal electrodes are operable as a bipolar electrode arrangement. The first and second spacing structures respectively maintain the arterial and aortal electrodes at a predefined distance away from the renal artery and aortal walls while electrical energy sufficient to ablate perivascular nerve tissue adjacent the renal artery and aortal walls is delivered by the bipolar electrode arrangement.
Description
RELATED PATENT DOCUMENTS

This application is a continuation of U.S. patent application Ser. No. 13/243,736, filed Sep. 23, 2011, which claims the benefit of Provisional Patent Application Ser. No. 61/423,439 filed Dec. 15, 2010; 61/434,136 filed Jan. 19, 2011; 61/503,378 filed Jun. 30, 2011; 61/503,382 filed Jun. 30, 2011; 61/503,386 filed Jun. 30, 2011; and to which priority is claimed pursuant to 35 U.S.C. §119(e) and which are hereby incorporated herein by reference.


SUMMARY

Devices, systems, and methods of the disclosure are directed to ablating target tissue of the body using a bipolar electrode arrangement that positions electrodes a distance away from body tissue during ablation of the target tissue. Devices, systems, and methods of the disclosure are directed to ablating target tissue adjacent a body vessel, chamber, cavity, or tissue structure using a bipolar electrode arrangement that positions electrodes a distance away from the body vessel, chamber, cavity, or tissue structure during ablation of the target tissue. Devices, systems, and methods are directed to denervating tissues that contribute to renal sympathetic nerve activity, such as perivascular renal nerves, using high frequency alternating current delivered to bipolar electrodes positioned a distance away from the inner wall of a renal artery during ablation.


Various embodiments of the disclosure are directed to ablation apparatuses and methods of ablation that include or use a positioning apparatus to maintain a gap between electrodes of a bipolar electrode arrangement and tissue of the body. The positioning apparatus is preferably configured to maintain positioning of electrodes a short distance away from body tissue during an ablation procedure. Although described in the context of ablation procedures performed from within a vessel hereinbelow, it is understood that positioning apparatuses consistent with the present disclosure may be implemented to maintain a gap between electrodes configured for RF bipolar ablation and a body vessel, chamber, cavity, or tissue structure (e.g., organ) during ablation.


In some embodiments, at least one electrode structure of a bipolar electrode arrangement includes a spacing structure configured to contact a body vessel, chamber, cavity, or tissue structure while holding one or more electrodes a distance away from the body vessel, chamber, cavity, or tissue structure during ablation. The other electrode structure of the bipolar electrode arrangement can include or exclude a spacing structure configured to contact a body vessel, chamber, cavity, or tissue structure while holding one or more electrodes a distance away from the body vessel, chamber, cavity, or tissue structure during ablation. The various electrodes can be of the same or a different type (e.g., same or different in terms of size, materials, number, or other physical, electrical, or mechanical attributes).


Various embodiments are directed to apparatuses which include a first catheter having a proximal end and a distal end, and a first spacing structure provided at the distal end of the first catheter. The first spacing structure is configured for deployment in a body vessel, chamber, cavity, organ, or tissue structure and to position at least one electrode at a predefined distance away from the body vessel, chamber, cavity, organ, or tissue structure. A second spacing structure is provided at the distal end of the first catheter or at a distal end of a second catheter. The second spacing structure is configured to support at least one electrode and for deployment at a body location spaced apart from the at least one electrode of the first spacing structure. The electrodes are operable as a bipolar electrode arrangement. At least the first spacing structure is configured to maintain the electrode at the predefined distance away from the body vessel, chamber, cavity, organ, or tissue structure while electrical energy sufficient to ablate target tissue adjacent the body vessel, chamber, cavity, organ, or tissue structure is delivered by the bipolar electrode arrangement. In some embodiments, each of the first and second spacing structures is configured to respectively maintain the electrodes at a predefined distance away from the body vessel, chamber, cavity, organ, or tissue structure while electrical energy sufficient to ablate the target tissue is delivered by the bipolar electrode arrangement.


According to other embodiments, an ablation apparatus includes a first catheter having a proximal end and a distal end, and a first spacing structure provided at the distal end of the first catheter. The first spacing structure is configured for deployment in a patient's renal artery and to position at least one arterial electrode at a predefined distance away from a wall of the renal artery. A second spacing structure is provided at the distal end of the first catheter or at a distal end of a second catheter. The second spacing structure is configured for deployment in the patient's aorta proximate the renal artery and to position at least one aortal electrode at a predefined distance away from a wall of the aorta. The arterial and aortal electrodes are operable as a bipolar electrode arrangement. Each of the first and second spacing structures are configured to respectively maintain the arterial and aortal electrodes at a predefined distance away from the renal artery and aortal walls while electrical energy sufficient to ablate perivascular nerve tissue adjacent the renal artery and aortal walls is delivered by the bipolar electrode arrangement.


Further embodiments are directed to methods involving causing a first support structure situated within or at a body vessel, chamber, cavity, organ, or tissue structure to transform between a low-profile introduction configuration and a larger-profile deployed configuration, and maintaining space between an ablation electrode arrangement and the body vessel, chamber, cavity, organ, or tissue structure using the first support structure in the deployed configuration. Methods also involve ablating target tissue adjacent the body vessel, chamber, cavity, organ, or tissue structure using an electrode arrangement and a another electrode arrangement spaced apart from the electrode arrangement while the first support structure is in the deployed configuration, and causing the first support structure to transform from the larger-profile deployed configuration to the low-profile introduction configuration after ablating the target tissue.


According to some embodiments, methods involve causing a second support structure situated within or at a body vessel, chamber, cavity, organ, or tissue structure to transform between a low-profile introduction configuration and a larger-profile deployed configuration, and maintaining space between the electrode arrangement and the body vessel, chamber, cavity, organ, or tissue structure using the second support structure in the deployed configuration. Methods further involve ablating target tissue adjacent the body vessel, chamber, cavity, organ, or tissue structure using the electrode arrangements while the first and second support structures are in the deployed configuration, and causing the first and second support structures to transform from the larger-profile deployed configuration to the low-profile introduction configuration after ablating the target tissue.


These and other features can be understood in view of the following detailed discussion and the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is an illustration of a right kidney and renal vasculature including a renal artery branching laterally from the abdominal aorta;



FIGS. 2A and 2B illustrate sympathetic innervation of the renal artery;



FIG. 3A illustrates various tissue layers of the wall of the renal artery;



FIGS. 3B and 3C illustrate a portion of a renal nerve;



FIG. 4 illustrates computer modeling of heat distribution through a vessel wall generated by an RF electrode placed in contact with the inner wall of the vessel;



FIG. 5 illustrates computer modeling of heat distribution through the same vessel wall generated by an RF electrode placed in a non-contacting relationship with the inner wall of the vessel in accordance with various embodiments;



FIG. 6 shows a bipolar off-wall RF electrode arrangement deployed in a patient's renal artery and in the patient's aorta in accordance with various embodiments;



FIG. 7 shows a bipolar off-wall RF electrode arrangement deployed in each of a patient's renal arteries in accordance with various embodiments;



FIGS. 8 and 9 show a bipolar off-wall RF electrode arrangement deployed in a patient's renal artery and in the patient's aorta in accordance with various embodiments;



FIG. 10 shows an off-wall RF electrode arrangement of an ablation catheter in a relatively collapsed configuration within an external sheath or guide catheter in accordance with various embodiments;



FIG. 11 illustrates a first off-wall electrode arrangement of an ablation catheter expanded and deployed in a renal artery, and a second off-wall electrode arrangement in a relatively collapsed configuration within an external sheath or guide catheter in accordance with various embodiments;



FIG. 12 shows a bipolar off-wall RF electrode arrangement deployed in each of a patient's renal arteries in accordance with various embodiments;



FIG. 13A shows an off-wall RF electrode arrangement of an ablation catheter in a collapsed configuration in accordance with various embodiments;



FIG. 13B shows the off-wall RF electrode arrangement of FIG. 13A in an expanded configuration in accordance with various embodiments;



FIG. 14 shows a bipolar off-wall RF electrode arrangement deployed in each of a patient's renal arteries in a collapsed configuration in accordance with various embodiments;



FIG. 15 shows a unipolar off-wall RF electrode arrangement positioned in a patient's renal artery and in an expanded configuration in accordance with various embodiments;



FIG. 16A shows a unipolar off-wall RF electrode arrangement of an ablation catheter in a collapsed configuration in accordance with various embodiments;



FIG. 16B shows the unipolar off-wall RF electrode arrangement of FIG. 16A in an expanded configuration in accordance with various embodiments;



FIG. 17 shows a unipolar off-wall RF electrode arrangement positioned in a patient's renal artery and in a collapsed configuration in accordance with various embodiments;



FIG. 18 shows the unipolar off-wall RF electrode arrangement of FIG. 17 in an expanded configuration in accordance with various embodiments;



FIG. 19 shows a representative RF renal therapy apparatus in accordance with various embodiments;



FIG. 20 shows an off-wall RF electrode arrangement biased against a side of the inner wall of the renal artery in accordance with various embodiments; and



FIG. 21 shows an embodiment of an off-wall spacing arrangement and an ultrasound ablation device encompassed by the off-wall spacing arrangement in accordance with various embodiments.





DESCRIPTION

Embodiments of the disclosure are directed to apparatuses and methods for ablating target tissue of the body. Embodiments of the disclosure are directed to apparatuses and methods for ablating perivascular renal nerves for the treatment of hypertension. Embodiments of the disclosure are directed to bipolar RF electrode arrangements configured to maintain positioning of electrodes in a space-apart relationship relative to an inner wall of a vessel during renal nerve ablation.


Ablation of perivascular renal nerves has been used as a treatment for hypertension. The autonomic nervous system includes afferent and efferent nerves connecting the kidneys to the central nervous system. At least some of these nerves travel in a perivascular location along the renal arteries. The exact locations of these nerves can be difficult to determine, but there is typically one or more ganglia just outside the aorta, near the junction with the renal artery, and nerves running along the renal arteries, with one or more additional ganglia. The ganglia are variable in number, size, and position, and can be located at the aortorenal junction, or around towards the anterior aspect of the aorta, or farther down along the renal artery, and can be on any side of the renal artery.


Conventional treatment approaches typically use monopolar radiofrequency (RF) electrodes placed in the renal artery to ablate the perivascular nerves, but with risk of artery wall injury. To control injury to the artery wall, one approach is to ablate at discrete locations along and around the artery, which simply limits the arterial injury to multiple smaller locations. With this approach, high current density typically occurs in the tissue closest to the electrode contact region, causing preferential heating and injury to the artery wall at each of the discrete locations. Multiple discrete ablations also extend the procedure time.


Due to the limitations of artery wall heating, previous approaches cannot treat certain patients, such as those with short or multiple renal arteries. Also, previous approaches require larger electrodes to reduce current density and improve heat transfer for artery wall cooling. In some situations, a lower-profile device may be desired, to reduce vascular complications or to facilitate radial artery access. A better approach to ablating renal sympathetic nerves for treatment of hypertension is needed, especially targeting the renal ganglia and further reducing arterial injury, preferably with lower profile devices.


Embodiments of the disclosure are directed to apparatuses and methods for RF ablation of renal autonomic ganglia and nerves for the treatment of hypertension with reduced renal artery injury. Various embodiments of the disclosure employ a bipolar off-wall RF electrode configuration to more effectively ablate nerves and ganglia near the renal ostium, without renal artery injury. Some embodiments employ a unipolar off-wall RF electrode configuration to more effectively ablate renal nerves and ganglia without renal artery injury.


Various embodiments of the disclosure are directed to apparatuses and methods for renal denervation for treating hypertension. Hypertension is a chronic medical condition in which the blood pressure is elevated. Persistent hypertension is a significant risk factor associated with a variety of adverse medical conditions, including heart attacks, heart failure, arterial aneurysms, and strokes. Persistent hypertension is a leading cause of chronic renal failure. Hyperactivity of the sympathetic nervous system serving the kidneys is associated with hypertension and its progression. Deactivation of nerves in the kidneys via renal denervation can reduce blood pressure, and may be a viable treatment option for many patients with hypertension who do not respond to conventional drugs.


The kidneys are instrumental in a number of body processes, including blood filtration, regulation of fluid balance, blood pressure control, electrolyte balance, and hormone production. One primary function of the kidneys is to remove toxins, mineral salts, and water from the blood to form urine. The kidneys receive about 20-25% of cardiac output through the renal arteries that branch left and right from the abdominal aorta, entering each kidney at the concave surface of the kidneys, the renal hilum.


Blood flows into the kidneys through the renal artery and the afferent arteriole, entering the filtration portion of the kidney, the renal corpuscle. The renal corpuscle is composed of the glomerulus, a thicket of capillaries, surrounded by a fluid-filled, cup-like sac called Bowman's capsule. Solutes in the blood are filtered through the very thin capillary walls of the glomerulus due to the pressure gradient that exists between the blood in the capillaries and the fluid in the Bowman's capsule. The pressure gradient is controlled by the contraction or dilation of the arterioles. After filtration occurs, the filtered blood moves through the efferent arteriole and the peritubular capillaries, converging in the interlobular veins, and finally exiting the kidney through the renal vein.


Particles and fluid filtered from the blood move from the Bowman's capsule through a number of tubules to a collecting duct. Urine is formed in the collecting duct and then exits through the ureter and bladder. The tubules are surrounded by the peritubular capillaries (containing the filtered blood). As the filtrate moves through the tubules and toward the collecting duct, nutrients, water, and electrolytes, such as sodium and chloride, are reabsorbed into the blood.


The kidneys are innervated by the renal plexus which emanates primarily from the aorticorenal ganglion. Renal ganglia are formed by the nerves of the renal plexus as the nerves follow along the course of the renal artery and into the kidney. The renal nerves are part of the autonomic nervous system which includes sympathetic and parasympathetic components. The sympathetic nervous system is known to be the system that provides the bodies “fight or flight” response, whereas the parasympathetic nervous system provides the “rest and digest” response. Stimulation of sympathetic nerve activity triggers the sympathetic response which causes the kidneys to increase production of hormones that increase vasoconstriction and fluid retention. This process is referred to as the renin-angiotensin-aldosterone-system (RAAS) response to increased renal sympathetic nerve activity.


In response to a reduction in blood volume, the kidneys secrete renin, which stimulates the production of angiotensin. Angiotensin causes blood vessels to constrict, resulting in increased blood pressure, and also stimulates the secretion of the hormone aldosterone from the adrenal cortex. Aldosterone causes the tubules of the kidneys to increase the reabsorption of sodium and water, which increases the volume of fluid in the body and blood pressure.


Congestive heart failure (CHF) is a condition that has been linked to kidney function. CHF occurs when the heart is unable to pump blood effectively throughout the body. When blood flow drops, renal function degrades because of insufficient perfusion of the blood within the renal corpuscles. The decreased blood flow to the kidneys triggers an increase in sympathetic nervous system activity (i.e., the RAAS becomes too active) that causes the kidneys to secrete hormones that increase fluid retention and vasorestriction. Fluid retention and vasorestriction in turn increases the peripheral resistance of the circulatory system, placing an even greater load on the heart, which diminishes blood flow further. If the deterioration in cardiac and renal functioning continues, eventually the body becomes overwhelmed, and an episode of heart failure decompensation occurs, often leading to hospitalization of the patient.



FIG. 1 is an illustration of a right kidney 10 and renal vasculature including a renal artery 12 branching laterally from the abdominal aorta 20. In FIG. 1, only the right kidney 10 is shown for purposes of simplicity of explanation, but reference will be made herein to both right and left kidneys and associated renal vasculature and nervous system structures, all of which are contemplated within the context of embodiments of the disclosure. The renal artery 12 is purposefully shown to be disproportionately larger than the right kidney 10 and abdominal aorta 20 in order to facilitate discussion of various features and embodiments of the present disclosure.


The right and left kidneys are supplied with blood from the right and left renal arteries that branch from respective right and left lateral surfaces of the abdominal aorta 20. Each of the right and left renal arteries is directed across the crus of the diaphragm, so as to form nearly a right angle with the abdominal aorta 20. The right and left renal arteries extend generally from the abdominal aorta 20 to respective renal sinuses proximate the hilum 17 of the kidneys, and branch into segmental arteries and then interlobular arteries within the kidney 10. The interlobular arteries radiate outward, penetrating the renal capsule and extending through the renal columns between the renal pyramids. Typically, the kidneys receive about 20% of total cardiac output which, for normal persons, represents about 1200 mL of blood flow through the kidneys per minute.


The primary function of the kidneys is to maintain water and electrolyte balance for the body by controlling the production and concentration of urine. In producing urine, the kidneys excrete wastes such as urea and ammonium. The kidneys also control reabsorption of glucose and amino acids, and are important in the production of hormones including vitamin D, renin and erythropoietin.


An important secondary function of the kidneys is to control metabolic homeostasis of the body. Controlling hemostatic functions include regulating electrolytes, acid-base balance, and blood pressure. For example, the kidneys are responsible for regulating blood volume and pressure by adjusting volume of water lost in the urine and releasing erythropoietin and renin, for example. The kidneys also regulate plasma ion concentrations (e.g., sodium, potassium, chloride ions, and calcium ion levels) by controlling the quantities lost in the urine and the synthesis of calcitrol. Other hemostatic functions controlled by the kidneys include stabilizing blood pH by controlling loss of hydrogen and bicarbonate ions in the urine, conserving valuable nutrients by preventing their excretion, and assisting the liver with detoxification.


Also shown in FIG. 1 is the right suprarenal gland 11, commonly referred to as the right adrenal gland. The suprarenal gland 11 is a star-shaped endocrine gland that rests on top of the kidney 10. The primary function of the suprarenal glands (left and right) is to regulate the stress response of the body through the synthesis of corticosteroids and catecholamines, including cortisol and adrenaline (epinephrine), respectively. Encompassing the kidneys 10, suprarenal glands 11, renal vessels 12, and adjacent perirenal fat is the renal fascia, e.g., Gerota's fascia, (not shown), which is a fascial pouch derived from extraperitoneal connective tissue.


The autonomic nervous system of the body controls involuntary actions of the smooth muscles in blood vessels, the digestive system, heart, and glands. The autonomic nervous system is divided into the sympathetic nervous system and the parasympathetic nervous system. In general terms, the parasympathetic nervous system prepares the body for rest by lowering heart rate, lowering blood pressure, and stimulating digestion. The sympathetic nervous system effectuates the body's fight-or-flight response by increasing heart rate, increasing blood pressure, and increasing metabolism.


In the autonomic nervous system, fibers originating from the central nervous system and extending to the various ganglia are referred to as preganglionic fibers, while those extending from the ganglia to the effector organ are referred to as postganglionic fibers. Activation of the sympathetic nervous system is effected through the release of adrenaline (epinephrine) and to a lesser extent norepinephrine from the suprarenal glands 11. This release of adrenaline is triggered by the neurotransmitter acetylcholine released from preganglionic sympathetic nerves.


The kidneys and ureters (not shown) are innervated by the renal nerves 14. FIGS. 1 and 2A-2B illustrate sympathetic innervation of the renal vasculature, primarily innervation of the renal artery 12. The primary functions of sympathetic innervation of the renal vasculature include regulation of renal blood flow and pressure, stimulation of renin release, and direct stimulation of water and sodium ion reabsorption.


Most of the nerves innervating the renal vasculature are sympathetic postganglionic fibers arising from the superior mesenteric ganglion 26. The renal nerves 14 extend generally axially along the renal arteries 12, enter the kidneys 10 at the hilum 17, follow the branches of the renal arteries 12 within the kidney 10, and extend to individual nephrons. Other renal ganglia, such as the renal ganglia 24, superior mesenteric ganglion 26, the left and right aorticorenal ganglia 22, and celiac ganglia 28 also innervate the renal vasculature. The celiac ganglion 28 is joined by the greater thoracic splanchnic nerve (greater TSN). The aorticorenal ganglia 26 is joined by the lesser thoracic splanchnic nerve (lesser TSN) and innervates the greater part of the renal plexus.


Sympathetic signals to the kidney 10 are communicated via innervated renal vasculature that originates primarily at spinal segments T10-T12 and L1. Parasympathetic signals originate primarily at spinal segments S2-S4 and from the medulla oblongata of the lower brain. Sympathetic nerve traffic travels through the sympathetic trunk ganglia, where some may synapse, while others synapse at the aorticorenal ganglion 22 (via the lesser thoracic splanchnic nerve, i.e., lesser TSN) and the renal ganglion 24 (via the least thoracic splanchnic nerve, i.e., least TSN). The postsynaptic sympathetic signals then travel along nerves 14 of the renal artery 12 to the kidney 10. Presynaptic parasympathetic signals travel to sites near the kidney 10 before they synapse on or near the kidney 10.


With particular reference to FIG. 2A, the renal artery 12, as with most arteries and arterioles, is lined with smooth muscle 34 that controls the diameter of the renal artery lumen 13. Smooth muscle, in general, is an involuntary non-striated muscle found within the media layer of large and small arteries and veins, as well as various organs. The glomeruli of the kidneys, for example, contain a smooth muscle-like cell called the mesangial cell. Smooth muscle is fundamentally different from skeletal muscle and cardiac muscle in terms of structure, function, excitation-contraction coupling, and mechanism of contraction.


Smooth muscle cells can be stimulated to contract or relax by the autonomic nervous system, but can also react on stimuli from neighboring cells and in response to hormones and blood borne electrolytes and agents (e.g., vasodilators or vasoconstrictors). Specialized smooth muscle cells within the afferent arteriole of the juxtaglomerular apparatus of kidney 10, for example, produces renin which activates the angiotension II system.


The renal nerves 14 innervate the smooth muscle 34 of the renal artery wall 15 and extend lengthwise in a generally axial or longitudinal manner along the renal artery wall 15. The smooth muscle 34 surrounds the renal artery circumferentially, and extends lengthwise in a direction generally transverse to the longitudinal orientation of the renal nerves 14, as is depicted in FIG. 2B.


The smooth muscle 34 of the renal artery 12 is under involuntary control of the autonomic nervous system. An increase in sympathetic activity, for example, tends to contract the smooth muscle 34, which reduces the diameter of the renal artery lumen 13 and decreases blood perfusion. A decrease in sympathetic activity tends to cause the smooth muscle 34 to relax, resulting in vessel dilation and an increase in the renal artery lumen diameter and blood perfusion. Conversely, increased parasympathetic activity tends to relax the smooth muscle 34, while decreased parasympathetic activity tends to cause smooth muscle contraction.



FIG. 3A shows a segment of a longitudinal cross-section through a renal artery, and illustrates various tissue layers of the wall 15 of the renal artery 12. The innermost layer of the renal artery 12 is the endothelium 30, which is the innermost layer of the intima 32 and is supported by an internal elastic membrane. The endothelium 30 is a single layer of cells that contacts the blood flowing though the vessel lumen 13. Endothelium cells are typically polygonal, oval, or fusiform, and have very distinct round or oval nuclei. Cells of the endothelium 30 are involved in several vascular functions, including control of blood pressure by way of vasoconstriction and vasodilation, blood clotting, and acting as a barrier layer between contents within the lumen 13 and surrounding tissue, such as the membrane of the intima 32 separating the intima 32 from the media 34, and the adventitia 36. The membrane or maceration of the intima 32 is a fine, transparent, colorless structure which is highly elastic, and commonly has a longitudinal corrugated pattern.


Adjacent the intima 32 is the media 33, which is the middle layer of the renal artery 12. The media is made up of smooth muscle 34 and elastic tissue. The media 33 can be readily identified by its color and by the transverse arrangement of its fibers. More particularly, the media 33 consists principally of bundles of smooth muscle fibers 34 arranged in a thin plate-like manner or lamellae and disposed circularly around the arterial wall 15. The outermost layer of the renal artery wall 15 is the adventitia 36, which is made up of connective tissue. The adventitia 36 includes fibroblast cells 38 that play an important role in wound healing.


A perivascular region 37 is shown adjacent and peripheral to the adventitia 36 of the renal artery wall 15. A renal nerve 14 is shown proximate the adventitia 36 and passing through a portion of the perivascular region 37. The renal nerve 14 is shown extending substantially longitudinally along the outer wall 15 of the renal artery 12. The main trunk of the renal nerves 14 generally lies in or on the adventitia 36 of the renal artery 12, often passing through the perivascular region 37, with certain branches coursing into the media 33 to enervate the renal artery smooth muscle 34.


Embodiments of the disclosure may be implemented to provide varying degrees of denervation therapy to innervated renal vasculature. For example, embodiments of the disclosure may provide for control of the extent and relative permanency of renal nerve impulse transmission interruption achieved by denervation therapy delivered using a treatment apparatus of the disclosure. The extent and relative permanency of renal nerve injury may be tailored to achieve a desired reduction in sympathetic nerve activity (including a partial or complete block) and to achieve a desired degree of permanency (including temporary or irreversible injury).


Returning to FIGS. 3B and 3C, the portion of the renal nerve 14 shown in FIGS. 3B and 3C includes bundles 14a of nerve fibers 14b each comprising axons or dendrites that originate or terminate on cell bodies or neurons located in ganglia or on the spinal cord, or in the brain. Supporting tissue structures 14c of the nerve 14 include the endoneurium (surrounding nerve axon fibers), perineurium (surrounds fiber groups to form a fascicle), and epineurium (binds fascicles into nerves), which serve to separate and support nerve fibers 14b and bundles 14a. In particular, the endoneurium, also referred to as the endoneurium tube or tubule, is a layer of delicate connective tissue that encloses the myelin sheath of a nerve fiber 14b within a fasciculus.


Major components of a neuron include the soma, which is the central part of the neuron that includes the nucleus, cellular extensions called dendrites, and axons, which are cable-like projections that carry nerve signals. The axon terminal contains synapses, which are specialized structures where neurotransmitter chemicals are released in order to communicate with target tissues. The axons of many neurons of the peripheral nervous system are sheathed in myelin, which is formed by a type of glial cell known as Schwann cells. The myelinating Schwann cells are wrapped around the axon, leaving the axolemma relatively uncovered at regularly spaced nodes, called nodes of Ranvier. Myelination of axons enables an especially rapid mode of electrical impulse propagation called saltation.


In some embodiments, a treatment apparatus of the disclosure may be implemented to deliver denervation therapy that causes transient and reversible injury to renal nerve fibers 14b. In other embodiments, a treatment apparatus of the disclosure may be implemented to deliver denervation therapy that causes more severe injury to renal nerve fibers 14b, which may be reversible if the therapy is terminated in a timely manner. In preferred embodiments, a treatment apparatus of the disclosure may be implemented to deliver denervation therapy that causes severe and irreversible injury to renal nerve fibers 14b, resulting in permanent cessation of renal sympathetic nerve activity. For example, a treatment apparatus may be implemented to deliver a denervation therapy that disrupts nerve fiber morphology to a degree sufficient to physically separate the endoneurium tube of the nerve fiber 14b, which can prevent regeneration and re-innervation processes.


By way of example, and in accordance with Seddon's classification as is known in the art, a treatment apparatus of the disclosure may be implemented to deliver a denervation therapy that interrupts conduction of nerve impulses along the renal nerve fibers 14b by imparting damage to the renal nerve fibers 14b consistent with neruapraxia. Neurapraxia describes nerve damage in which there is no disruption of the nerve fiber 14b or its sheath. In this case, there is an interruption in conduction of the nerve impulse down the nerve fiber, with recovery taking place within hours to months without true regeneration, as Wallerian degeneration does not occur. Wallerian degeneration refers to a process in which the part of the axon separated from the neuron's cell nucleus degenerates. This process is also known as anterograde degeneration. Neurapraxia is the mildest form of nerve injury that may be imparted to renal nerve fibers 14b by use of a treatment apparatus according to embodiments of the disclosure.


A treatment apparatus may be implemented to interrupt conduction of nerve impulses along the renal nerve fibers 14b by imparting damage to the renal nerve fibers consistent with axonotmesis. Axonotmesis involves loss of the relative continuity of the axon of a nerve fiber and its covering of myelin, but preservation of the connective tissue framework of the nerve fiber. In this case, the encapsulating support tissue 14c of the nerve fiber 14b are preserved. Because axonal continuity is lost, Wallerian degeneration occurs. Recovery from axonotmesis occurs only through regeneration of the axons, a process requiring time on the order of several weeks or months. Electrically, the nerve fiber 14b shows rapid and complete degeneration. Regeneration and re-innervation may occur as long as the endoneural tubes are intact.


A treatment apparatus may be implemented to interrupt conduction of nerve impulses along the renal nerve fibers 14b by imparting damage to the renal nerve fibers 14b consistent with neurotmesis. Neurotmesis, according to Seddon's classification, is the most serious nerve injury in the scheme. In this type of injury, both the nerve fiber 14b and the nerve sheath are disrupted. While partial recovery may occur, complete recovery is not possible. Neurotmesis involves loss of continuity of the axon and the encapsulating connective tissue 14c, resulting in a complete loss of autonomic function, in the case of renal nerve fibers 14b. If the nerve fiber 14b has been completely divided, axonal regeneration causes a neuroma to form in the proximal stump.


A more stratified classification of neurotmesis nerve damage may be found by reference to the Sunderland System as is known in the art. The Sunderland System defines five degrees of nerve damage, the first two of which correspond closely with neurapraxia and axonotmesis of Seddon's classification. The latter three Sunderland System classifications describe different levels of neurotmesis nerve damage.


The first and second degrees of nerve injury in the Sunderland system are analogous to Seddon's neurapraxia and axonotmesis, respectively. Third degree nerve injury, according to the Sunderland System, involves disruption of the endoneurium, with the epineurium and perineurium remaining intact. Recovery may range from poor to complete depending on the degree of intrafascicular fibrosis. A fourth degree nerve injury involves interruption of all neural and supporting elements, with the epineurium remaining intact. The nerve is usually enlarged. Fifth degree nerve injury involves complete transection of the nerve fiber 14b with loss of continuity.


Turning now to FIGS. 4 and 5, there is illustrated computer modeling of heat distribution through a vessel wall generated by an RF electrode situated within the lumen of the vessel. In FIG. 4, the electrode is situated in direct contact with the inner wall of the vessel. In FIG. 5, the electrode is situated in a non-contacting (off-wall) relationship with respect to the inner wall of the vessel in accordance with various embodiments. It is readily apparent that temperatures of the vessel's inner wall resulting from the non-contact electrode-to-tissue interface shown in FIG. 5 are significantly lower than vessel inner wall temperatures resulting from the direct contact electrode-to-tissue interface of FIG. 4.



FIG. 4 shows the heat distribution profile 16 within the renal artery wall 15 produced by an ablation electrode 92 of a catheter 90 placed in direct contact with the vessel's inner wall 15a. The catheter 90 includes a conductor 94 that runs the length of the catheter and is connected to the electrode 92 situated at the distal end of the catheter 90. In the configuration shown in FIG. 4, the relative positioning of the electrode 92 and inner wall 15a of the renal artery wall 15 defines a direct contact electrode-to-tissue interface 91.


The heat distribution profile 16 of FIG. 4 demonstrates that the artery wall tissue at or nearest the artery's inner wall 15a is subject to relatively high temperatures. As can be seen in FIG. 4, heat produced by the electrode 92 at the direct contact electrode-to-tissue interface 91 is greatest at the inner wall 15a and decreases as a function of increasing distance away from the electrode 92. For example, a heating zone 16a associated with the highest temperatures produced by the ablation electrode 92 extends nearly the entire thickness of the artery wall 15. A zone 16b of lower temperatures relative to zone 16a extends radially outward from zone 16a, beyond the outer wall 15b of the renal artery 12, and into perivascular space adjacent the renal artery 12. A relatively cool zone 16c is shown extending radially outward relative to zones 16a and 16b. In this simulation, zone 16a is associated with temperatures required to ablate tissue which includes renal arterial wall tissue and perivascular renal nerves.



FIG. 5 shows the ablation electrode 92 of catheter 90 situated in a spaced-apart relationship relative to the inner wall 15a of the renal artery 12. In the configuration shown in FIG. 5, the relative positioning of the electrode 92 and inner wall 15a of the renal artery wall 15 defines a non-contact electrode-to-tissue interface 93. As can be seen in FIG. 5, the heat distribution profile 18 differs significantly from that shown in FIG. 4.


Importantly, zone 18a, which is associated with the highest temperatures (ablation temperatures), is translated or shifted outwardly away from the inner wall 15a and towards the outer wall 15b and perivascular space adjacent the renal artery 12. Zone 18a encompasses an outer portion of the adventitia of the renal artery wall 15 and encompasses a significant portion of the perivascular space adjacent the renal artery 12. As such, renal nerves and ganglia included within the adventitial tissue and perivascular space are subject to ablative temperatures, while the endothelium at the inner wall 15a of the renal artery 12 is maintained at a temperature which does not cause permanent injury to the inner wall tissue.


Off-wall electrode configurations according to various embodiments can reduce the RF current density in the artery wall 15, as the current spreads out somewhat as it passes between the electrode 102 and the artery wall 15 through the blood. This provides a sort of fluidic “virtual electrode” and results in less heating of the artery wall 15 due to the lower current density. According to various embodiments, structures that hold one or more electrodes at a prescribed distance away from the artery wall 15 preferably provide for passive cooling of the artery wall 15 during ablation by blood flowing through the artery 12. Separating the electrode(s) from the artery wall 15 by a structure that allows blood to pass along the artery wall 15 provides more effective cooling of the artery wall 15 (and the electrode 102), further reducing thermal injury to the artery wall 15. The current density in the target perivascular tissue can also be somewhat decreased, but the cooler artery wall temperatures allow greater overall power to be delivered safely, in order to achieve sufficient current density in the target tissue to ablate the target tissue.


Various embodiments of the disclosure are directed to apparatuses and methods for RF ablation of perivascular renal nerves for treatment of hypertension, employing one or more bipolar off-wall RF electrode configurations to more effectively ablate renal nerves and ganglia near the renal ostium, while avoiding injury to the renal artery. A bipolar off-wall RF electrode arrangement of the disclosure includes multiple electrodes held slightly away from the artery and/or aortal wall, resulting in decreased current density and improved cooling from the blood to reduce arterial and/or aortal injury while maintaining target tissue at ablation temperatures.


According to some embodiments, an off-wall electrode arrangement maintains positioning of one or more electrodes at a separation distance ranging from about 0.5 mm to about 3 mm away from a vessel wall. According to other embodiments, an off-wall electrode arrangement maintains positioning of one or more electrodes at a separation distance ranging from about 1 mm to about 1.5 mm away from a vessel wall. Prior approaches have used an RF electrode placed in direct contact with the renal artery, for example, but have had difficulty in repositioning the electrode to complete ablation while minimizing injury to the artery wall due to peak current density and heating at the wall contact points.


With reference to FIG. 6, a bipolar off-wall RF electrode arrangement is shown deployed in a patient's renal artery 12 and in the patient's aorta 20. The bipolar electrode arrangement 40 shown in FIG. 6 includes an electrode arrangement 50 deployed in the lumen 13 of the renal artery 12 and an electrode arrangement 60 deployed in the aorta 20 at a location near the aortorenal junction. Each of the electrode arrangements 50 and 60 includes one or more RF electrodes which are maintained a predefined distance away from the renal artery wall and the aortal wall, respectively. The electrode arrangements 50 and 60 are configured to operate as a bipolar RF electrode configuration.



FIG. 7 shows another embodiment of a bipolar off-wall RF electrode arrangement. In the embodiment illustrated in FIG. 7, the bipolar electrode arrangement 45 includes an electrode arrangement 55 deployed in the lumen 13a of one of the patient's renal arteries 12a. A second bipolar electrode arrangement 65 is shown deployed in a lumen 13b of the patient's other renal artery 12b. Each of the electrode arrangements 55 and 65 includes one or more RF electrodes which are maintained a predefined distance away from the respective renal artery walls. The electrode arrangements 50 and 60 are configured to operate as a bipolar RF electrode configuration.


It is noted that, in some embodiments, a ground pad may be used in the configurations shown in FIGS. 6 and 7. For example, bipolar ablation may be performed using selected electrodes of one or both of the bipolar electrode arrangements shown in the Figures and the ground pad. For configurations that include a ground pad, renal denervation may be selectively performed in a unipolar ablation mode or a bipolar ablation mode. It is further noted that the ablation zone is close to the electrode in a unipolar ablation configuration, but also close to the two electrode arrangements in a bipolar ablation configuration. Also, it is understood that the electric field strength decreases as a function of the square of distance from the electrodes.


According to various embodiments, and as illustrated in FIGS. 8 and 9, an RF ablation catheter 100 includes a first electrode arrangement 102 with at least one and preferably multiple electrodes 104 mounted on a first expandable structure 101 to position the electrodes 104 near, but not in direct contact with, the inner artery wall 15a. Spacing features 106 hold the electrodes 104 a controlled distance from the renal artery wall 15a for effective wall cooling and to decrease current density at the artery wall 15a.


A second electrode arrangement 122 is incorporated into the same catheter, or into a modified guide catheter or sheath, similarly positions electrodes 104 near the wall of the aorta 20. The second electrode arrangement 122 includes at least one and preferably multiple electrodes 104 mounted on a second expandable structure 123 to position the electrodes 104 near, but not in direct contact with, the inner wall of the aorta 20 proximate the aortorenal junction. Spacing features 106 maintain the electrodes 104 at a controlled distance from the aortal wall for effective wall cooling and to decrease current density at the aortal wall.


Bipolar activation by an external control unit passes RF energy between aortic and renal artery electrodes 104 of the first and second the electrode arrangements 102, 122 to preferentially ablate perivascular tissue near the renal artery ostium where significant autonomic ganglia are typically located. In some embodiments, an optional helical actuation wire 110 can be provided within a lumen of the ablation catheter 100. The helical actuation wire 110 can be displaced in a distal or proximal direction to selectively collapse and expand the first and second expandable structures 101 and 123 of the ablation catheter 100.



FIG. 9 schematically illustrates RF current passing between two different pairs of electrodes 104 mounted on the first and second expandable structures 101, 123, and passing through the target tissue. Control of which electrodes 104 are energized and in what combinations and timing is determined automatically by a control unit which supplies RF energy to the electrodes 104. For example, selected electrodes 104 of each of the first and second electrode arrangements 102 can be activated to define or contribute to different RF current paths. Bifurcated or multiple renal artery anatomies can be treated with this approach as well. By control of which electrodes 104 are active, switching between electrodes 104, and positioning the electrodes 104 away from the vessel walls, effective heating of the perivascular tissue containing significant nerves and ganglia is achieved while minimizing thermal injury to the renal artery 12 and the aorta 20.


Each electrode 104 in the first electrode arrangement 102 has a corresponding insulated conductor to connect to the external control unit. The control unit energizes electrodes 104 of the first and second electrode arrangements 102 and 122 in a prescribed pattern and sequence. Monitoring of the tissue impedance between various electrode pairs offers improved evaluation of the extent of tissue ablation. It is understood that some of the electrodes 104 in the first electrode arrangement 102 can be coupled in series if desired.


RF current passes between an electrode 104 in the renal artery 12 and an electrode 104 in the aorta 20, passing through the blood for a short distance before passing through the vessel walls and the intervening tissue. Since blood effectively cools the vessel wall, the target tissue is ablated without injury to the vessel walls. An infusion of fluid into the vessel(s) can reduce the conductivity of the blood to reduce current flow directly through the blood so that current preferentially passes through target tissues. A fluid infusion can also reduce effects on the blood and potential fouling of the electrode surface, allowing smaller electrodes to be used.


As is shown in FIGS. 10 and 11, the ablation catheter 100 has a low profile introduction configuration. FIG. 10 shows the distal end of the ablation catheter 100 in a relatively collapsed configuration within an external sheath or guide catheter 130. The flexibility of the first and second electrode arrangement 102 and 122 of the ablation catheter 100 provides for enhanced navigation and advancement of the catheter 110 through the patient's vasculature.


In some embodiments, the first and second expandable structures 101 and 123 incorporate a shape-memory or a superelastic member configured to assume desired shapes when in their respective expanded configurations, such as those shown in FIGS. 8 and 9, for example. For example, the first and second expandable structures 101 and 123 can each incorporate a shape-memory or a superelastic helical wire. The helical wire of the first expandable structure 101 has a first diameter when assuming its deployed configuration. The helical wire of the second expandable structure 123 has a second diameter when assuming its deployed configuration. As can be seen in the embodiment illustrated in FIGS. 8 and 9, the second diameter is greater than the first diameter. In some embodiments, the second diameter is greater than the first diameter by a factor of at least 1.5. In other embodiments, the second diameter is greater than the first diameter by a factor of at least 2.


Although shown as a continuous unitary member in FIGS. 8 and 9, separate shape-memory or superelastic members may be used for each of the first and second expandable structures 101 and 123. A common sheath or separate sheaths may be used to deliver separate first and second expandable structures 101 and 123 to the renal artery 12 and aorta 20, respectively.


A transition region 112 may be defined between the separate shaping members, and include a material or component that facilitates independent movement of the separate members during expansion and collapsing. In some configurations, a continuous shape-memory or superelastic member can be fashioned with distal and proximal sections configured to assume desired shapes when in their respective expanded configurations.


In FIG. 11, the first electrode arrangement 102 is shown expanded and deployed in the renal artery 12. The first electrode arrangement 102 is preferably self-expanding, in that it transforms from its introduction configuration, shown in FIG. 10, to its deployed configuration, shown in FIG. 11, when the external sheath or guide catheter 100 is retracted from the first electrode arrangement 102. The spacing features 106 keep the electrodes 104 a short distance away from the artery wall. A variety of spacing features 106 can be utilized, including bumps or curves, struts or baskets, spherical or cylindrical elements, and the like. The spacing features 106 are chosen to minimize interference with blood flow past the artery wall 15a to maximize the cooling effect on the artery wall 15a.



FIG. 11 further shows the second electrode arrangement 122 about to expand as the sheath 130 is retracted. When in its expanded configuration, the spacing features 106 of the second electrode arrangement 122 keep the electrodes 104 a short distance away from the aorta wall 20. The perivascular tissues near the aortorenal ostium are ablated, including the target renal nerves and ganglia in that region. After completion of the ablation procedure, the first and second electrode arrangement 102 and 122 are collapsed, such as by advancing an external sheath 130 over the arrangements 102, 122. The ablation catheter 100 may be manipulated to advance the first electrode arrangement 102 into the contralateral renal artery 12, and the procedure may be repeated.


According to some embodiments, the first electrode arrangement 102 can incorporate a single electrode 104, with a positioning arrangement configured to hold the electrode 104 near the center of the renal artery 12. Rather than having the first and second electrode arrangements 102 and 122 on the same catheter, the second electrode arrangement 122 can be incorporated into the external sheath, guide catheter, or other device to provide more flexibility in positioning electrodes 104 of the second electrode arrangement 122. Multiple electrodes 104 of the first electrode arrangement 102 can be energized in parallel, and multiple electrodes 104 in the second electrode arrangement 122 can be energized in parallel, in a bipolar arrangement between first and second electrode arrangements 102 and 122. The second electrode arrangement 122 can be configured to deploy electrodes 104 at the opposite side of the aorta 20, or all around the aorta 20.


In accordance with various embodiments, apparatuses and methods are directed to bipolar RF ablation of renal autonomic ganglia and nerves with reduced renal artery injury using dual ablation catheters. Embodiments according to FIG. 12-14 use off-wall RF electrodes in each renal artery 12a and 12b to quickly and effectively ablate renal sympathetic nerves and ganglia without renal artery injury.


In the embodiments shown in FIGS. 12-14, a sheath 210 is shown positioned in the aorta 20 inferior to the aortorenal junction. It is understood that the sheath 210 may alternatively be positioned superior to the aortorenal junction. The sheath 210 has a lumen through which two ablation catheters 220 and 240 are advanced into respective renal arteries 12a and 12b. According to some embodiments, the sheath 210 has a diameter of about 6 French (Fr.) and each of the ablation catheters 220 and 240 has a diameter of about 3 Fr. In some embodiments, the ablation catheters 220 and 240 are configured as infusion catheters, allowing for imaging contrast injection into the renal arteries 12a and 12b.


Each of the ablation catheters 220 and 240 includes an RF electrode 224 encompassed by a centering basket 226. In a deployed configuration, as shown in FIG. 12, each centering basket 226 expands radially and makes contact with discrete circumferential locations of the respective inner renal artery walls. The centering baskets 226 are configured to position the RF electrode 224 preferably at a center location within the lumens 13a, 13b of the respective renal arteries 12a, 12b.


As is shown in FIGS. 12 and 14, a first electrode arrangement 222a is advanced into one renal artery 12a and a second electrode arrangement 222b is advanced into the other renal artery 12b. Each centering basket 226 is expanded to hold its respective electrode 224 a predetermined distance from the renal artery walls to ensure effective wall cooling from blood flow, and to decrease current density at the artery walls. It is noted that the first and second electrode arrangements 222a and 222b may be provided at the distal portions of a branched catheter, or two small separate catheters can be used.


Bipolar activation by an external control unit passes RF energy between the right and left renal artery electrodes 224 to preferentially ablate perivascular tissue near the renal artery ostium where significant autonomic ganglia are typically located. By positioning the electrodes 224 away from the vessel walls, the perivascular tissue is effectively heated while minimizing thermal injury to the renal artery and the aorta. FIG. 12 schematically illustrates RF current passing between electrodes 224 positioned in both renal arteries 12a and 12b, and passing through the target tissue. The control unit automatically controls the energizing of the electrodes 224. Since more effective heating of a larger amount of perivascular tissue is obtained without injury to the renal arteries 12a and 12b, even bifurcated or multiple renal artery anatomies may be treatable with this approach.


According to some embodiments, guidewires 221, 241 are provided to aid in positioning the first and second electrode arrangements 222a and 222b in the renal arteries 12a and 12b. The guidewires 221, 241 may have limited freedom to move with respect to the ablation catheters 220 and 140, so a curved wire tip can be employed and manipulated as needed to gain access to the renal arteries 12a and 12b. When configured as infusion catheters, ablation catheters 220 and 240 can be used for imaging contrast injection.


As can be seen in FIGS. 13a and 13b, the ablation catheters 220 and 240 have a low profile introduction configuration. For simplicity of explanation, reference will be made to ablation catheter 220 in the following discussion, understanding that the description is equally applicable to ablation catheter 240. FIG. 13a shows a captured guidewire 221 and basket stop actuation of a self-collapsing centering basket 226. In the electrode arrangement 222, the electrode 224 is attached to the infusion catheter 220 by an insulated strut structure 228, which also provides for electrical power from the external control unit. The centering basket 226 is either non-conductive or is insulated.


A basket actuation stop 223 is attached to the guidewire 221. After positioning the guidewire 221 as desired and advancing the ablation catheter 220 to the treatment position, the guidewire 221 and basket actuation stop 223 are retracted to actuate the centering basket 226 and maintain the basket 226 in a deployed configuration. The electrode ends can be insulated to avoid current concentrations near the ends of the electrode 224. After treatment, the guidewire 221 is advanced to allow the centering basket 226 to collapse. A sheath 210 (shown in FIG. 12) can be used to further collapse the centering basket 226 if needed. The centering basket 226 can be preferentially closed according to some embodiments (e.g., a self-collapsing structure).


In some embodiments, a somewhat larger basket configuration can be utilized that is self-expanding (but not necessarily self-collapsing), such as by use of an external sheath or a pull wire to collapse the centering basket 226. In other embodiments, the centering basket 226 need not be biased for self-expansion or self-collapsing, but may be push-pulled actuated or actuated using some combination of push, pull, and/or sheath arrangements.



FIG. 14 shows ablation catheters 222a and 222b in a collapsed configuration deployed respectively within the patient's left and right renal arteries 12a and 12b. Access to the lumen 13a and 13b of the left and right renal arteries 12a and 12b is facilitated by manipulation of guide wires 221 and 241. Having accessed the left and right renal arteries 12a and 12b using guidewires 221 and 241, ablation catheters 220 and 240 are advanced over their respective guide wires 221 and 241 and into renal arteries 12a and 12b using an over-the-wire technique. Proper positioning of the electrode arrangements 222a and 222b may be facilitated using imaging contrast injection into the ablation catheters 220a and 220b. In some embodiments, a radiopaque marker band can be provided at one or more locations of the ablation catheters 220 and 240 to enhance imaging of catheter positioning. With the electrode arrangements 222a and 222b positioned at desired locations within the renal arteries 12a and 12b, the captured guidewire 221 is pulled in a proximal direction toward the basket actuation stop 223. As discussed above, retraction of the guidewire 221 forces the centering basket 226 to compress longitudinally and expand radially into its deployed configuration, as is shown in FIG. 12.


An external control unit energizes the electrodes 204 of the electrode arrangements 222a and 222b in a bipolar manner. Monitoring of the tissue impedance between the electrodes 204 can be used for evaluation of the extent of tissue ablation. RF current passes between the electrodes 204 in the renal arteries 13a and 13b, passing through the blood for a short distance before passing through the vessel walls and the intervening tissue. Since blood effectively cools the vessel wall, the target tissue is ablated without injury to the vessel walls. An infusion of fluid through the ablation catheters 220 and 240 can locally reduce the conductivity of the blood to reduce current flow directly through the blood so that current preferentially passes through target tissues. As previously discussed, fluid infusion can also reduce effects on the blood and potential fouling of the electrode surface, allowing smaller electrodes to be used.


According to some embodiments, the infusion ablation catheters 220 and 240 can be D-shaped to maximize infusion space. Other electrode configurations can be used, including multiple electrodes in each renal artery. Spacer configurations other than the illustrated centering basket 226 can be used to keep the electrodes a minimum distance from the artery walls. One electrode arrangement can be incorporated into a small infusion catheter similar to those shown, with the other electrode arrangement incorporated into an external sheath, guide catheter, or other device, to provide more flexibility in positioning the ablation regions or to improve profile or contrast injection capacity. A separate ground can be provided, such as with conventional skin ground pads or conductive portions of a guide catheter or sheath. Instead of or in addition to the bipolar RF configuration as shown, unipolar configurations with the ablation electrode(s) and the separate ground can be utilized.


Turning now to FIGS. 15-18, there is shown an embodiment of an ablation catheter 320 configured for ablating renal nerves using a unipolar configuration. Embodiments according to FIGS. 15-18 use a low profile device with an off-wall RF electrode in the renal artery to quickly and effectively ablate renal sympathetic nerves and ganglia without renal artery injury. This approach allows use of a relatively small (as compared to conventional access approaches) access sheath to reduce femoral vascular complications, and can also be used with radial artery access.


The ablation catheter 320 includes features similar to those previously described. Because the ablation catheter 320 is configured for individual deployment as compared to the dual ablation catheter configurations shown in FIGS. 12-14, somewhat larger components may be used if desired. For example, and in accordance with various embodiments, the ablation catheter 320 preferably has a diameter of about 4 Fr. or less, and the delivery sheath 310 preferably has a diameter of about 4 Fr. or less. The ablation catheter 320 may be configured as an infusion catheter.


An electrode arrangement 322 is shown provided at a distal end of the ablation catheter 320. The electrode arrangement 322 has a similar construction and functionality as those previously described with regard to FIGS. 12-14, and includes an electrode 324 centered within an expandable centering basket 326 and insulated struts 328. For example, and with reference to FIGS. 17 and 18, the expandable centering basket 326 can be activated in the manner described above by retracting a captured guidewire 321 and basket stop 323 into forced engagement with the centering basket 326. Expanded views of the electrode arrangement 320 in non-deployed and deployed configurations are respectively shown in FIGS. 16A and 16B.


For example, apparatuses in accordance with various embodiments include a small infusion catheter 320 with an ablation region 322 near the distal end of the catheter 320. The ablation region 322 has an RF electrode 224 and a centering basket 326. The ablation region 322 is advanced from either a superior (see FIGS. 17 and 18) or an inferior (see FIG. 15) aortal location into the renal artery 12. The centering basket 322 is expanded to hold the electrode 324 a minimum distance from the renal artery wall to guarantee effective wall cooling from blood flow, and to decrease current density at the artery wall. RF energy provided by an external control unit is passed between the electrode 324 and a ground pad to preferentially ablate perivascular tissue where the target autonomic nerves are located. By positioning the electrode 324 away from the vessel walls, the perivascular tissue is effectively heated while minimizing thermal injury to the renal artery.


A guidewire 321 is provided to aid in positioning the ablation region 322 in the renal artery 12. The guidewire 321 may have limited freedom to move with respect to the ablation catheter 320, so a curved wire tip can be manipulated as needed to gain access to the renal artery 12. The ablation catheter 320 may be configured as an infusion catheter, and can be used for imaging contrast injection.


In the embodiments according to FIGS. 15-18, an external control unit is used to energize the electrode 324 in a controlled manner. Monitoring of the tissue impedance can be used for evaluation of the extent of tissue ablation. RF current passes between the electrode 324 and the ground (such as an external ground pad), passing through the blood for a short distance before passing through the vessel walls and the perivascular tissue. Since blood effectively cools the vessel wall, the target tissue is ablated without injury to the vessel walls. An infusion of fluid through the ablation catheter 320 can locally reduce the conductivity of the blood to reduce current flow directly through the blood so that current preferentially passes through target tissues. A fluid infusion will also reduce effects on the blood and potential fouling of the electrode surface, allowing a smaller electrode to be used.


After ablating renal arterial tissue in the one renal artery, the guidewire 321 is advanced to allow the centering basket 326 to collapse, and the apparatus is repositioned in the contralateral renal artery for treatment. The sheath 310 can be used to further collapse the centering basket 326 if needed. The centering basket 326 can be preferentially closed (“self-collapsing”). Since more effective heating of a larger amount of perivascular tissue is obtained without injury to the renal artery, even bifurcated or multiple renal artery anatomies may be treatable with this approach.


Various embodiments provide for a reduce profile configuration by using a captured guidewire 321. Alternatively, a standard guidewire can be used, by adding an actuation filament or sleeve, with slightly larger profile. For example, a non-conductive filament can pull back on the centering basket stop 323 to deploy the centering basket 326. In other embodiments, a self-expanding basket 326 can be used, and an outer sheath 310 is added. The outer sheath 310 is advanced over the centering basket 326 for low-profile introduction, and is retracted to allow the basket 326 to expand. Other electrode configurations can be used, including multiple electrodes 324 and centering baskets 326 in each renal artery. Spacer configurations other than the illustrated centering basket 326 can be used to keep the electrodes 324 a minimum distance from the artery walls. Instead of a monopolar configuration with a separate ground pad, the ground can be conductive portions of a guide catheter or sheath, or multiple electrodes 324 can be used in a bipolar configuration.



FIG. 19 shows a representative RF renal therapy apparatus 400 in accordance with various embodiments of the disclosure. The apparatus 400 illustrated in FIG. 19 includes external electrode activation circuitry 420 which comprises power control circuitry 422 and timing control circuitry 424. The external electrode activation circuitry 420, which includes an RF generator, is coupled to temperature measuring circuitry 428 and may be coupled to an optional impedance sensor 426. An ablation catheter 402 includes a shaft 404 that incorporates a lumen arrangement 405 configured for receiving a variety of components, such as conductors, pharmacological agents, actuator elements, obturators, sensors, or other components as needed or desired. A delivery sheath 403 may be used to facilitate deployment of the catheter 402 into the arterial system via a percutaneous access site 406 in the embodiment shown in FIG. 19. The distal end of the catheter 402 may include a hinge mechanism 456 to facilitate navigation of the catheter's distal tip around turn of approximately 90° from the aorta to a renal artery 12.


The RF generator of the external electrode activation circuitry 420 may include a pad electrode 430 that is configured to comfortably engage the patient's back or other portion of the body near the kidneys. Radiofrequency energy produced by the RF generator is coupled to the flexible electrode arrangement 100 at the distal end of the ablation catheter 402 by the conductor arrangement disposed in the lumen of the catheter's shaft 404.


Renal denervation therapy using the apparatus shown in FIG. 19 can be performed in a unipolar or monopolar mode using the flexible electrode arrangement 100 positioned within the renal artery 12 and the pad electrode 430 positioned on the patient's back, with the RF generator operating in a monopolar mode. In other implementations, multiple flexible electrode arrangements, such as those shown in previous figures, can be configured for operation in a bipolar configuration, in which case the electrode pad 330 is not needed. Representative bipolar configurations include a pair of flexible electrode arrangements, one in each of the patient's renal arteries. Other representative bipolar configurations include one flexible electrode arrangement positioned in one renal artery and another flexible electrode arrangement positioned in the aorta proximate the aortorenal junction. The radiofrequency energy flows through the flexible electrode arrangement or multiple arrangements in accordance with a predetermined activation sequence (e.g., sequential or concurrent) and into the adjacent tissue of the renal artery. In general, when renal artery or aortal tissue temperatures rise above about 113° F. (50° C.), protein is permanently damaged (including those of renal nerve fibers). If heated over about 65° C. and up to 100° C., cell walls break and oil separates from water. Above about 100° C., tissue desiccates.


According to some embodiments, the electrode activation circuitry 420 is configured to control activation and deactivation of one or more electrodes of the flexible electrode arrangement(s) in accordance with a predetermined energy delivery protocol and in response to signals received from temperature measuring circuitry 428. The electrode activation circuitry 420 controls radiofrequency energy delivered to the electrodes of the flexible electrode arrangement(s) so as to maintain the current densities at a level sufficient to cause heating of the target tissue preferably to a temperature of at least about 55° C.


In some embodiments, one or more temperature sensors are situated at the flexible electrode arrangement(s) and provide for continuous monitoring of renal artery tissue temperatures, and RF generator power is automatically adjusted so that the target temperatures are achieved and maintained. An impedance sensor arrangement 426 may be used to measure and monitor electrical impedance during RF denervation therapy, and the power and timing of the RF generator 420 may be moderated based on the impedance measurements or a combination of impedance and temperature measurements. The size of the ablated area is determined largely by the size, shape, number, and arrangement of the electrodes supported by the flexible electrode arrangement(s), the power applied, and the duration of time the energy is applied.


With reference to FIG. 20, there is shown an embodiment of an ablation catheter 520 configured for ablating renal nerves using either a unipolar configuration or a bipolar configuration. In the embodiment shown in FIG. 20, an electrode arrangement 522 is provided at a distal end of the catheter 520 and is encompassed by a spacing basket 529. The spacing basket 529, unlike the centering basket implementations discussed previously, is dimensioned to be smaller than the diameter of the lumen 13 of the renal artery 12. In this configuration, the electrode 524 is preferably positioned at an off-center location within the lumen 13 and biased against an inner wall portion of the renal artery 12.


In use, the ablation catheter 520 is advanced into the renal artery 12 via a delivery sheath 521. When positioned at a desired location within the renal artery 12, the spacing basket 529 is expanded to hold the electrode 524 a desired distance from the renal artery wall, such as between about 0.5 and 1.0 mm away from the renal artery wall. A biasing force produced by the shaft of the catheter 520, which can be augmented by adjusting the position of delivery sheath 521 relative to the catheter's shaft, maintains the expanded spacing basket 529 and electrode 524 in proper position during ablation. The spacing basket 529 can be moved circumferentially about the inner wall of the renal artery 12 to create a circumferential lesion with reduced injury to the renal artery's inner wall. The spacing basket 529, although biased against the wall of the renal artery 12, maintains the electrode 524 at a predefined distance from the artery wall during ablation, which provides effective cooling from blood flow and decreases current density at the artery wall. Biasing, bending, or deflection structures can be provided to bias the spacing basket 529 toward the artery wall as desired. Various aspects of a centered larger-basket device as shown in the figures can be applied to the non-centered smaller basket configurations.



FIG. 21 shows an embodiment of an ablation catheter 620 deployed within the lumen 13 of a patient's renal artery 12. In this embodiment, the ablation catheter 620 includes a centering basket 629 which encompasses an ultrasound ablation device 624. The centering basket 629 is preferably configured in a manner previously described. The ultrasound ablation device 624 preferably includes one or more cylindrical ultrasound transducers which can focus acoustic energy at target tissue and at desired depths within and beyond (e.g., perivascular space) the wall of the renal artery 12. In some embodiments, the ultrasound ablation device 624 can operate at cooler temperatures than RF ablation electrodes due to its ability to focus acoustic energy efficiently at target tissue, which reduces the risk of injury to the inner wall of the renal artery 12.


Representative examples of ultrasound transducers configured for renal denervation are disclosed in commonly owned co-pending U.S. patent application Ser. No. 13/086,116, which is incorporated herein by reference. For example, ultrasound ablation device 624 can be configured as a multiple element intraluminal ultrasound cylindrical phased array, with a multiplicity of ultrasound transducers distributed around the periphery of a cylindrical member. The ultrasound ablation device 624 may be used for imaging and ablation when operated in an imaging mode and an ablation mode, respectively. In some embodiments, renal ablation using the ultrasound ablation device 624 may be conducted under magnetic resonance imaging guidance.


Various embodiments disclosed herein are generally described in the context of ablation of perivascular renal nerves for control of hypertension. It is understood, however, that embodiments of the disclosure have applicability in other contexts, such as performing ablation from within other vessels of the body, including other arteries, veins, and vasculature (e.g., cardiac and urinary vasculature and vessels), and other tissues of the body, including various organs.


It is to be understood that even though numerous characteristics of various embodiments have been set forth in the foregoing description, together with details of the structure and function of various embodiments, this detailed description is illustrative only, and changes may be made in detail, especially in matters of structure and arrangements of parts illustrated by the various embodiments to the full extent indicated by the broad general meaning of the terms in which the appended claims are expressed.

Claims
  • 1. An apparatus, comprising: a catheter having a proximal end and a distal end;a first structure provided at the distal end of the catheter, the first structure configured for deployment in a renal artery of a patient, the first structure configured to position at least a first electrode within the renal artery;a second structure provided at the distal end of the catheter proximal to the first structure, the second structure configured for deployment in an aorta of the patient, proximate the renal artery and to position at least a second electrode within the aorta;the at least first and second electrodes being off-wall electrodes and operable as a bipolar electrode arrangement; andeach of the first and second structures respectively being configured to maintain the at least first and second electrodes within the renal artery and the aorta, respectively, and the apparatus being configured to deliver electrical energy sufficient to ablate perivascular tissue comprising renal nerves and ganglia proximate a renal ostium through the bipolar electrode arrangement;wherein the first structure extends from a distal end of the second structure; andwherein the first and second structures each comprise helical structures.
  • 2. The apparatus of claim 1, wherein: the first structure includes a helical wire having a first diameter in its deployed configuration; andthe second structure includes a second helical wire having a second diameter in its deployed configuration;wherein the second diameter is greater than the first diameter.
  • 3. The apparatus of claim 2, comprising a sheath defining a lumen dimensioned to receive the apparatus in a non-deployed configuration, wherein the sheath is retractable to allow the first and second helical wires to expand to their helical deployed configurations.
  • 4. The apparatus of claim 1, wherein the first structure comprises a first helical structure having a first diameter, the second structure comprises a second helical structure having a second diameter that is greater than the first diameter by a factor of 2 or more.
  • 5. The apparatus of claim 1, wherein each off-wall electrode is configured to be maintained at a separation distance ranging from 0.5 mm to 3 mm away from an adjacent vessel wall.
  • 6. An apparatus, comprising: a catheter having a proximal end and a distal end;a first expandable structure provided at the distal end of the catheter, the first expandable structure including at least one off-wall electrode and being configured for deployment in a renal artery of a patient;a second expandable structure provided at the distal end of the catheter, the second expandable structure including at least one off-wall electrode and being configured for deployment in an aorta of a patient spaced apart from the at least one electrode of the first expandable structure, wherein the first expandable structure extends from a distal end of the second expandable structure;the respective at least one electrodes of the first and second expandable structures operable as a bipolar electrode arrangement; andthe first and second expandable structures being configured to maintain their respective at least one electrodes in the spaced apart configuration within the renal artery and aorta, respectively, and the apparatus being configured to deliver electrical energy sufficient to ablate target perivascular tissue comprising renal nerves and ganglia adjacent a renal ostium through the bipolar electrode arrangement.
  • 7. The apparatus of claim 6, wherein at least one of the first and second expandable structures comprises a helical wire.
  • 8. The apparatus of claim 6, further comprising an external control unit electrically coupled to each of the at least one electrodes and configured to supply energy to each of the at least one electrodes in accordance with one or more predetermined activation patterns or sequences.
  • 9. The apparatus of claim 6, wherein one or both of the first and second expandable structures comprises a shape-memory member or a superelastic member.
  • 10. The apparatus of claim 6, wherein the first expandable structure comprises a first expandable helical structure having a first diameter, the second expandable structure comprises a second expandable helical structure having a second diameter that is greater than the first diameter by a factor of 2 or more.
  • 11. The apparatus of claim 6, wherein each off-wall electrode is configured to be maintained at a separation distance ranging from 0.5 mm to 3 mm away from an adjacent vessel wall.
  • 12. A method of ablating tissue, comprising: inserting a catheter into a patient's body, the catheter having first and second helical support structures disposed at a distal end thereof, each of the first and second helical support structures including at least one off wall electrode;positioning the first helical support structure inside a renal artery;positioning the second helical support structure inside an aorta, wherein the electrodes on the respective first and second helical support structures are configured for operation as a bipolar electrode arrangement;ablating target perivascular tissue comprising renal nerves and ganglia adjacent a renal ostium by delivering energy through the bipolar electrode arrangement while the first and second helical support structures remain in the renal artery and aorta, respectively.
  • 13. The method of claim 12, wherein the first helical support structure has a first diameter, the second helical support structure comprises has a second diameter that is greater than the first diameter by a factor of 2 or more.
  • 14. The method of claim 12, wherein each off-wall electrode is maintained at a separation distance ranging from 0.5 mm to 3 mm away from an adjacent vessel wall.
US Referenced Citations (1503)
Number Name Date Kind
164184 Kidder Jun 1875 A
852787 Hoerner May 1907 A
921973 Gillett et al. May 1909 A
976733 Gilliland Nov 1910 A
1167014 O'Brien Jan 1916 A
2505358 Gusberg et al. Apr 1950 A
2701559 Cooper Feb 1955 A
3108593 Glassman Oct 1963 A
3108594 Glassman Oct 1963 A
3540431 Mobin Nov 1970 A
3952747 Kimmell Apr 1976 A
3996938 Clark, III Dec 1976 A
4046150 Schwartz et al. Sep 1977 A
4290427 Chin Sep 1981 A
4402686 Medel Sep 1983 A
4483341 Witteles et al. Nov 1984 A
4531943 Van Tassel et al. Jul 1985 A
4574804 Kurwa Mar 1986 A
4587975 Salo et al. May 1986 A
4649936 Ungar et al. Mar 1987 A
4682596 Bales et al. Jul 1987 A
4709698 Johnston et al. Dec 1987 A
4765331 Petruzzi et al. Aug 1988 A
4770653 Shturman Sep 1988 A
4784132 Fox et al. Nov 1988 A
4784162 Ricks et al. Nov 1988 A
4785806 Deckelbaum et al. Nov 1988 A
4788975 Shturman et al. Dec 1988 A
4790310 Ginsburg et al. Dec 1988 A
4799479 Spears Jan 1989 A
4823791 D'Amelio et al. Apr 1989 A
4830003 Wolff et al. May 1989 A
4849484 Heard Jul 1989 A
4862886 Clarke et al. Sep 1989 A
4887605 Angelsen et al. Dec 1989 A
4890623 Cook et al. Jan 1990 A
4920979 Bullara et al. May 1990 A
4938766 Jarvik Jul 1990 A
4955377 Lennox et al. Sep 1990 A
4976711 Parins et al. Dec 1990 A
5034010 Kittrell et al. Jul 1991 A
5052402 Bencini et al. Oct 1991 A
5053033 Clarke et al. Oct 1991 A
5071424 Reger et al. Dec 1991 A
5074871 Groshong et al. Dec 1991 A
5098429 Sterzer et al. Mar 1992 A
5098431 Rydell Mar 1992 A
5109859 Jenkins May 1992 A
5125928 Parins et al. Jun 1992 A
5129396 Rosen et al. Jul 1992 A
5139496 Hed Aug 1992 A
5143836 Hartman et al. Sep 1992 A
5156610 Reger et al. Oct 1992 A
5158564 Schnepp-Pesch Oct 1992 A
5170802 Mehra Dec 1992 A
5178620 Eggers et al. Jan 1993 A
5178625 Groshong et al. Jan 1993 A
5190540 Lee Mar 1993 A
5211651 Reger et al. May 1993 A
5234407 Teirstein et al. Aug 1993 A
5242441 Avitall Sep 1993 A
5251634 Weinberg et al. Oct 1993 A
5255679 Imran Oct 1993 A
5263493 Avitall Nov 1993 A
5267954 Nita et al. Dec 1993 A
5277201 Stern et al. Jan 1994 A
5282484 Reger et al. Feb 1994 A
5286254 Shapland et al. Feb 1994 A
5290306 Trotta et al. Mar 1994 A
5295484 Marcus Mar 1994 A
5297564 Love et al. Mar 1994 A
5300068 Rosar et al. Apr 1994 A
5301683 Durkan Apr 1994 A
5304115 Pflueger et al. Apr 1994 A
5304121 Sahatjian Apr 1994 A
5304171 Gregory et al. Apr 1994 A
5304173 Kittrell et al. Apr 1994 A
5306250 March et al. Apr 1994 A
5312328 Nita et al. May 1994 A
5314466 Stern et al. May 1994 A
5322064 Lundquist Jun 1994 A
5324255 Passafaro et al. Jun 1994 A
5326341 Lew et al. Jul 1994 A
5326342 Plueger et al. Jul 1994 A
5330518 Neilson et al. Jul 1994 A
5333614 Feiring Aug 1994 A
5342292 Nita et al. Aug 1994 A
5344395 Whalen et al. Sep 1994 A
5364392 Warner et al. Nov 1994 A
5365172 Hrovat et al. Nov 1994 A
5368557 Nita et al. Nov 1994 A
5368558 Nita et al. Nov 1994 A
5380274 Nita et al. Jan 1995 A
5380319 Saito et al. Jan 1995 A
5382228 Nita et al. Jan 1995 A
5383874 Jackson et al. Jan 1995 A
5383917 Desai et al. Jan 1995 A
5397301 Pflueger et al. Mar 1995 A
5397339 Desai Mar 1995 A
5401272 Perkins et al. Mar 1995 A
5403311 Abele et al. Apr 1995 A
5405318 Nita et al. Apr 1995 A
5405346 Grundy et al. Apr 1995 A
5409000 Imran Apr 1995 A
5417672 Nita et al. May 1995 A
5419767 Eggers et al. May 1995 A
5427118 Nita et al. Jun 1995 A
5432876 Appeldorn et al. Jul 1995 A
5441498 Perkins et al. Aug 1995 A
5447509 Mills et al. Sep 1995 A
5451207 Yock et al. Sep 1995 A
5453091 Taylor et al. Sep 1995 A
5454788 Walker et al. Oct 1995 A
5454809 Janssen Oct 1995 A
5455029 Hartman et al. Oct 1995 A
5456682 Edwards et al. Oct 1995 A
5457042 Hartman et al. Oct 1995 A
5471982 Edwards et al. Dec 1995 A
5474530 Passafaro et al. Dec 1995 A
5478351 Meade et al. Dec 1995 A
5496311 Abele et al. Mar 1996 A
5496312 Klicek et al. Mar 1996 A
5498261 Strul Mar 1996 A
5505201 Grill et al. Apr 1996 A
5505730 Edwards Apr 1996 A
5507744 Tay et al. Apr 1996 A
5512051 Wang et al. Apr 1996 A
5522873 Jackman et al. Jun 1996 A
5531520 Grimson et al. Jul 1996 A
5540656 Pflueger et al. Jul 1996 A
5540679 Fram et al. Jul 1996 A
5540681 Strul et al. Jul 1996 A
5542917 Nita et al. Aug 1996 A
5545132 Fagan et al. Aug 1996 A
5545161 Imran Aug 1996 A
5562100 Kittrell et al. Oct 1996 A
5571122 Kelly et al. Nov 1996 A
5571151 Gregory Nov 1996 A
5573531 Gregory et al. Nov 1996 A
5573533 Strul Nov 1996 A
5584831 McKay Dec 1996 A
5584872 Lafontaine et al. Dec 1996 A
5588962 Nicholas et al. Dec 1996 A
5599346 Edwards et al. Feb 1997 A
5601526 Chapelon et al. Feb 1997 A
5609606 O'Boyle et al. Mar 1997 A
5613979 Trotta et al. Mar 1997 A
5626576 Janssen May 1997 A
5630837 Crowley May 1997 A
5637090 McGee et al. Jun 1997 A
5643255 Organ Jul 1997 A
5643297 Nordgren et al. Jul 1997 A
5647847 Lafontaine et al. Jul 1997 A
5649923 Gregory et al. Jul 1997 A
5651780 Jackson et al. Jul 1997 A
5653684 Laptewicz et al. Aug 1997 A
5662671 Barbut et al. Sep 1997 A
5665062 Houser Sep 1997 A
5665098 Kelly et al. Sep 1997 A
5666964 Meilus Sep 1997 A
5667490 Keith et al. Sep 1997 A
5672174 Gough et al. Sep 1997 A
5676693 Lafontaine Oct 1997 A
5678296 Fleischhacker et al. Oct 1997 A
5681282 Eggers et al. Oct 1997 A
RE35656 Feinberg Nov 1997 E
5687737 Branham et al. Nov 1997 A
5688266 Edwards et al. Nov 1997 A
5693015 Walker et al. Dec 1997 A
5693029 Leonhardt et al. Dec 1997 A
5693043 Kittrell et al. Dec 1997 A
5693082 Warner et al. Dec 1997 A
5695504 Gifford et al. Dec 1997 A
5697369 Long, Jr. et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5702386 Stern et al. Dec 1997 A
5702433 Taylor et al. Dec 1997 A
5706809 Littmann et al. Jan 1998 A
5713942 Stern et al. Feb 1998 A
5715819 Svenson et al. Feb 1998 A
5735846 Panescu et al. Apr 1998 A
5741214 Ouchi et al. Apr 1998 A
5741248 Stern et al. Apr 1998 A
5741249 Moss et al. Apr 1998 A
5743903 Stern et al. Apr 1998 A
5748347 Erickson May 1998 A
5749914 Janssen May 1998 A
5755682 Knudson et al. May 1998 A
5755715 Stern et al. May 1998 A
5755753 Knowlton et al. May 1998 A
5769847 Panescu et al. Jun 1998 A
5769880 Truckai et al. Jun 1998 A
5775338 Hastings Jul 1998 A
5776174 Van Tassel Jul 1998 A
5779698 Clayman et al. Jul 1998 A
5782760 Schaer Jul 1998 A
5785702 Murphy et al. Jul 1998 A
5797849 Vesely et al. Aug 1998 A
5797903 Swanson et al. Aug 1998 A
5800484 Gough et al. Sep 1998 A
5800494 Campbell et al. Sep 1998 A
5807306 Shapland et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5810803 Moss et al. Sep 1998 A
5810810 Tay et al. Sep 1998 A
5817092 Behl Oct 1998 A
5817113 Gifford et al. Oct 1998 A
5817144 Gregory et al. Oct 1998 A
5823956 Roth et al. Oct 1998 A
5827203 Nita et al. Oct 1998 A
5827268 Laufer Oct 1998 A
5829447 Stevens et al. Nov 1998 A
5830213 Panescu et al. Nov 1998 A
5830222 Makower Nov 1998 A
5832228 Holden et al. Nov 1998 A
5833593 Liprie Nov 1998 A
5836874 Swanson et al. Nov 1998 A
5840076 Swanson et al. Nov 1998 A
5843016 Lugnani et al. Dec 1998 A
5846238 Jackson et al. Dec 1998 A
5846239 Swanson et al. Dec 1998 A
5846245 McCarthy et al. Dec 1998 A
5848969 Panescu et al. Dec 1998 A
5853411 Whayne et al. Dec 1998 A
5855614 Stevens et al. Jan 1999 A
5860974 Abele Jan 1999 A
5865801 Houser Feb 1999 A
5868735 Lafontaine et al. Feb 1999 A
5868736 Swanson et al. Feb 1999 A
5871483 Jackson et al. Feb 1999 A
5871524 Knowlton et al. Feb 1999 A
5875782 Ferrari et al. Mar 1999 A
5876369 Houser Mar 1999 A
5876374 Alba et al. Mar 1999 A
5876397 Edelman et al. Mar 1999 A
5879348 Owens et al. Mar 1999 A
5891114 Chien et al. Apr 1999 A
5891135 Jackson et al. Apr 1999 A
5891136 McGee et al. Apr 1999 A
5891138 Tu et al. Apr 1999 A
5895378 Nita Apr 1999 A
5897552 Edwards et al. Apr 1999 A
5902328 Lafontaine et al. May 1999 A
5904651 Swanson et al. May 1999 A
5904667 Falwell et al. May 1999 A
5904697 Gifford, III et al. May 1999 A
5904709 Arndt et al. May 1999 A
5906614 Stern et al. May 1999 A
5906623 Peterson May 1999 A
5906636 Casscells et al. May 1999 A
5916192 Nita et al. Jun 1999 A
5916227 Keith et al. Jun 1999 A
5916239 Geddes et al. Jun 1999 A
5919219 Knowlton et al. Jul 1999 A
5924424 Stevens et al. Jul 1999 A
5925038 Panescu et al. Jul 1999 A
5934284 Plaia et al. Aug 1999 A
5935063 Nguyen Aug 1999 A
5938670 Keith et al. Aug 1999 A
5947977 Slepian et al. Sep 1999 A
5948011 Knowlton et al. Sep 1999 A
5951494 Wang et al. Sep 1999 A
5951539 Nita et al. Sep 1999 A
5954717 Behl et al. Sep 1999 A
5957882 Nita et al. Sep 1999 A
5957941 Ream et al. Sep 1999 A
5957969 Warner et al. Sep 1999 A
5961513 Swanson et al. Oct 1999 A
5964757 Ponzi et al. Oct 1999 A
5967976 Larsen et al. Oct 1999 A
5967978 Littmann et al. Oct 1999 A
5967984 Chu et al. Oct 1999 A
5971975 Mills et al. Oct 1999 A
5972026 Laufer et al. Oct 1999 A
5980563 Tu et al. Nov 1999 A
5989208 Nita et al. Nov 1999 A
5989284 Laufer Nov 1999 A
5993462 Pomeranz et al. Nov 1999 A
5997497 Nita et al. Dec 1999 A
5999678 Murphy et al. Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6004316 Laufer et al. Dec 1999 A
6007514 Nita Dec 1999 A
6010522 Barbut et al. Jan 2000 A
6013033 Berger et al. Jan 2000 A
6014590 Whayne et al. Jan 2000 A
6022309 Celliers et al. Feb 2000 A
6024740 Lesh et al. Feb 2000 A
6030611 Gorecki et al. Feb 2000 A
6032675 Rubinsky et al. Mar 2000 A
6033397 Laufer et al. Mar 2000 A
6033398 Farley et al. Mar 2000 A
6036687 Laufer et al. Mar 2000 A
6036689 Tu et al. Mar 2000 A
6041260 Stern et al. Mar 2000 A
6050994 Sherman et al. Apr 2000 A
6056744 Edwards May 2000 A
6056746 Goble et al. May 2000 A
6063085 Tay et al. May 2000 A
6066096 Smith et al. May 2000 A
6066139 Ryan et al. May 2000 A
6068638 Makower May 2000 A
6068653 Lafontaine May 2000 A
6071277 Farley et al. Jun 2000 A
6071278 Panescu et al. Jun 2000 A
6078839 Carson Jun 2000 A
6079414 Roth Jun 2000 A
6080171 Keith et al. Jun 2000 A
6081749 Ingle et al. Jun 2000 A
6086581 Reynolds et al. Jul 2000 A
6091995 Ingle et al. Jul 2000 A
6093166 Knudson et al. Jul 2000 A
6096021 Helm et al. Aug 2000 A
6099526 Whayne et al. Aug 2000 A
6102908 Tu et al. Aug 2000 A
6106477 Miesel et al. Aug 2000 A
6110187 Donlon et al. Aug 2000 A
6110192 Ravenscroft et al. Aug 2000 A
6114311 Parmacek et al. Sep 2000 A
6117101 Diederich et al. Sep 2000 A
6117128 Gregory Sep 2000 A
6120476 Fung et al. Sep 2000 A
6120516 Selmon et al. Sep 2000 A
6121775 Pearlman Sep 2000 A
6123679 Lafaut et al. Sep 2000 A
6123682 Knudson et al. Sep 2000 A
6123702 Swanson et al. Sep 2000 A
6123703 Tu et al. Sep 2000 A
6123718 Tu et al. Sep 2000 A
6129725 Tu et al. Oct 2000 A
6135997 Laufer et al. Oct 2000 A
6142991 Schatzberger et al. Nov 2000 A
6142993 Whayne et al. Nov 2000 A
6149647 Tu et al. Nov 2000 A
6152899 Farley et al. Nov 2000 A
6152912 Jansen et al. Nov 2000 A
6156046 Passafaro et al. Dec 2000 A
6158250 Tibbals et al. Dec 2000 A
6159187 Park et al. Dec 2000 A
6159225 Makower Dec 2000 A
6161048 Sluijter et al. Dec 2000 A
6162184 Swanson et al. Dec 2000 A
6165163 Chien et al. Dec 2000 A
6165172 Farley et al. Dec 2000 A
6165187 Reger et al. Dec 2000 A
6168594 Lafontaine et al. Jan 2001 B1
6171321 Gifford, III et al. Jan 2001 B1
6179832 Jones et al. Jan 2001 B1
6179835 Panescu et al. Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6183468 Swanson et al. Feb 2001 B1
6183486 Snow et al. Feb 2001 B1
6190379 Heuser et al. Feb 2001 B1
6191862 Swanson et al. Feb 2001 B1
6197021 Panescu et al. Mar 2001 B1
6200266 Shokrollahi et al. Mar 2001 B1
6203537 Adrian Mar 2001 B1
6203561 Ramee et al. Mar 2001 B1
6210406 Webster Apr 2001 B1
6211247 Goodman Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6219577 Brown, III et al. Apr 2001 B1
6228076 Winston et al. May 2001 B1
6228109 Tu et al. May 2001 B1
6231516 Keilman et al. May 2001 B1
6231587 Makower May 2001 B1
6235044 Root et al. May 2001 B1
6236883 Ciaccio et al. May 2001 B1
6237605 Vaska et al. May 2001 B1
6238389 Paddock et al. May 2001 B1
6238392 Long May 2001 B1
6241666 Pomeranz et al. Jun 2001 B1
6241753 Knowlton Jun 2001 B1
6245020 Moore et al. Jun 2001 B1
6245045 Stratienko Jun 2001 B1
6248126 Lesser et al. Jun 2001 B1
6251128 Knopp et al. Jun 2001 B1
6258087 Edwards et al. Jul 2001 B1
6273886 Edwards et al. Aug 2001 B1
6280466 Kugler et al. Aug 2001 B1
6283935 Laufer et al. Sep 2001 B1
6283959 Lalonde et al. Sep 2001 B1
6284743 Parmacek et al. Sep 2001 B1
6287323 Hammerslag Sep 2001 B1
6290696 Lafontaine Sep 2001 B1
6292695 Webster, Jr. et al. Sep 2001 B1
6293942 Goble et al. Sep 2001 B1
6293943 Panescu et al. Sep 2001 B1
6296619 Brisken et al. Oct 2001 B1
6298256 Meyer Oct 2001 B1
6299379 Lewis Oct 2001 B1
6299623 Wulfman Oct 2001 B1
6309379 Willard et al. Oct 2001 B1
6309399 Barbut et al. Oct 2001 B1
6311090 Knowlton Oct 2001 B1
6317615 KenKnight et al. Nov 2001 B1
6319242 Patterson et al. Nov 2001 B1
6319251 Tu et al. Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6325797 Stewart et al. Dec 2001 B1
6325799 Goble Dec 2001 B1
6328699 Eigler et al. Dec 2001 B1
6346074 Roth Feb 2002 B1
6346104 Daly et al. Feb 2002 B2
6350248 Knudson et al. Feb 2002 B1
6350276 Knowlton Feb 2002 B1
6353751 Swanson et al. Mar 2002 B1
6355029 Joye et al. Mar 2002 B1
6357447 Swanson et al. Mar 2002 B1
6361519 Knudson et al. Mar 2002 B1
6364840 Crowley Apr 2002 B1
6371965 Gifford, III et al. Apr 2002 B2
6375668 Gifford et al. Apr 2002 B1
6377854 Knowlton Apr 2002 B1
6377855 Knowlton Apr 2002 B1
6379352 Reynolds et al. Apr 2002 B1
6379373 Sawhney et al. Apr 2002 B1
6381497 Knowlton Apr 2002 B1
6381498 Knowlton Apr 2002 B1
6383151 Diederich et al. May 2002 B1
6387105 Gifford, III et al. May 2002 B1
6387380 Knowlton May 2002 B1
6389311 Whayne et al. May 2002 B1
6389314 Feiring May 2002 B2
6391024 Sun et al. May 2002 B1
6394096 Constantz May 2002 B1
6394956 Chandrasekaran et al. May 2002 B1
6398780 Farley et al. Jun 2002 B1
6398782 Pecor et al. Jun 2002 B1
6398792 O'Connor Jun 2002 B1
6401720 Stevens et al. Jun 2002 B1
6402719 Ponzi et al. Jun 2002 B1
6405090 Knowlton Jun 2002 B1
6409723 Edwards Jun 2002 B1
6413255 Stern Jul 2002 B1
6421559 Pearlman Jul 2002 B1
6423057 He et al. Jul 2002 B1
6425867 Vaezy et al. Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6427118 Suzuki Jul 2002 B1
6428534 Joye et al. Aug 2002 B1
6428536 Panescu et al. Aug 2002 B2
6430446 Knowlton Aug 2002 B1
6432102 Joye et al. Aug 2002 B2
6436056 Wang et al. Aug 2002 B1
6438424 Knowlton Aug 2002 B1
6440125 Rentrop Aug 2002 B1
6442413 Silver Aug 2002 B1
6443965 Gifford, III et al. Sep 2002 B1
6445939 Swanson et al. Sep 2002 B1
6447505 McGovern et al. Sep 2002 B2
6447509 Bonnet et al. Sep 2002 B1
6451034 Gifford, III et al. Sep 2002 B1
6451044 Naghavi et al. Sep 2002 B1
6453202 Knowlton Sep 2002 B1
6454737 Nita et al. Sep 2002 B1
6454757 Nita et al. Sep 2002 B1
6454775 Demarais et al. Sep 2002 B1
6458098 Kanesaka Oct 2002 B1
6461378 Knowlton Oct 2002 B1
6468276 McKay Oct 2002 B1
6468297 Williams et al. Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6470219 Edwards et al. Oct 2002 B1
6471696 Berube et al. Oct 2002 B1
6475213 Whayne et al. Nov 2002 B1
6475215 Tanrisever Nov 2002 B1
6475238 Fedida et al. Nov 2002 B1
6477426 Fenn et al. Nov 2002 B1
6480745 Nelson et al. Nov 2002 B2
6481704 Koster et al. Nov 2002 B1
6482202 Goble et al. Nov 2002 B1
6484052 Visuri et al. Nov 2002 B1
6485489 Teirstein et al. Nov 2002 B2
6488679 Swanson et al. Dec 2002 B1
6489307 Phillips et al. Dec 2002 B1
6491705 Gifford, III et al. Dec 2002 B2
6494891 Cornish et al. Dec 2002 B1
6497711 Plaia et al. Dec 2002 B1
6500172 Panescu et al. Dec 2002 B1
6500174 Maguire et al. Dec 2002 B1
6508765 Suorsa et al. Jan 2003 B2
6508804 Sarge et al. Jan 2003 B2
6508815 Strul et al. Jan 2003 B1
6511478 Burnside et al. Jan 2003 B1
6511496 Huter et al. Jan 2003 B1
6511500 Rahme Jan 2003 B1
6514236 Stratienko Feb 2003 B1
6514245 Williams et al. Feb 2003 B1
6514248 Eggers et al. Feb 2003 B1
6517534 McGovern et al. Feb 2003 B1
6517572 Kugler et al. Feb 2003 B2
6522913 Swanson et al. Feb 2003 B2
6522926 Kieval et al. Feb 2003 B1
6524299 Tran et al. Feb 2003 B1
6527765 Kelman et al. Mar 2003 B2
6527769 Langberg et al. Mar 2003 B2
6540761 Houser Apr 2003 B2
6542781 Koblish et al. Apr 2003 B1
6544780 Wang Apr 2003 B1
6546272 MacKinnon et al. Apr 2003 B1
6547788 Maguire et al. Apr 2003 B1
6549800 Atalar et al. Apr 2003 B1
6552796 Magnin et al. Apr 2003 B2
6554780 Sampson et al. Apr 2003 B1
6558381 Ingle et al. May 2003 B2
6558382 Jahns et al. May 2003 B2
6564096 Mest May 2003 B2
6565582 Gifford, III et al. May 2003 B2
6569109 Sakurai et al. May 2003 B2
6569177 Dillard et al. May 2003 B1
6570659 Schmitt May 2003 B2
6572551 Smith et al. Jun 2003 B1
6572612 Stewart et al. Jun 2003 B2
6577902 Laufer et al. Jun 2003 B1
6579308 Jansen et al. Jun 2003 B1
6579311 Makower Jun 2003 B1
6582423 Thapliyal et al. Jun 2003 B1
6589238 Edwards et al. Jul 2003 B2
6592526 Lenker Jul 2003 B1
6592567 Levin et al. Jul 2003 B1
6595959 Stratienko Jul 2003 B1
6600956 Maschino et al. Jul 2003 B2
6602242 Fung et al. Aug 2003 B1
6602246 Joye et al. Aug 2003 B1
6605056 Eidenschink et al. Aug 2003 B2
6605084 Acker et al. Aug 2003 B2
6623452 Chien et al. Sep 2003 B2
6623453 Guibert et al. Sep 2003 B1
6632193 Davison et al. Oct 2003 B1
6632196 Houser Oct 2003 B1
6645223 Boyle et al. Nov 2003 B2
6648854 Patterson et al. Nov 2003 B1
6648878 Lafontaine Nov 2003 B2
6648879 Joye et al. Nov 2003 B2
6651672 Roth Nov 2003 B2
6652513 Panescu et al. Nov 2003 B2
6652515 Maguire et al. Nov 2003 B1
6656136 Weng et al. Dec 2003 B1
6658279 Swanson et al. Dec 2003 B2
6659981 Stewart et al. Dec 2003 B2
6666858 Lafontaine Dec 2003 B2
6666863 Wentzel et al. Dec 2003 B2
6669655 Acker et al. Dec 2003 B1
6669692 Nelson et al. Dec 2003 B1
6673040 Samson et al. Jan 2004 B1
6673064 Rentrop Jan 2004 B1
6673066 Werneth Jan 2004 B2
6673090 Root et al. Jan 2004 B2
6673101 Fitzgerald et al. Jan 2004 B1
6673290 Whayne et al. Jan 2004 B1
6676678 Gifford, III et al. Jan 2004 B2
6679268 Stevens et al. Jan 2004 B2
6681773 Murphy et al. Jan 2004 B2
6682541 Gifford, III et al. Jan 2004 B1
6684098 Oshio et al. Jan 2004 B2
6685732 Kramer Feb 2004 B2
6685733 Dae et al. Feb 2004 B1
6689086 Nita et al. Feb 2004 B1
6689148 Sawhney et al. Feb 2004 B2
6690181 Dowdeswell et al. Feb 2004 B1
6692490 Edwards Feb 2004 B1
6695830 Vigil et al. Feb 2004 B2
6695857 Gifford, III et al. Feb 2004 B2
6699241 Rappaport et al. Mar 2004 B2
6699257 Gifford, III et al. Mar 2004 B2
6702748 Nita et al. Mar 2004 B1
6702811 Stewart et al. Mar 2004 B2
6706010 Miki et al. Mar 2004 B1
6706011 Murphy-Chutorian et al. Mar 2004 B1
6706037 Zvuloni et al. Mar 2004 B2
6709431 Lafontaine Mar 2004 B2
6711429 Gilboa et al. Mar 2004 B1
6712815 Sampson et al. Mar 2004 B2
6714822 King et al. Mar 2004 B2
6716184 Vaezy et al. Apr 2004 B2
6720350 Kunz et al. Apr 2004 B2
6723043 Kleeman et al. Apr 2004 B2
6723064 Babaev Apr 2004 B2
6736811 Panescu et al. May 2004 B2
6743184 Sampson et al. Jun 2004 B2
6746401 Panescu Jun 2004 B2
6746464 Makower Jun 2004 B1
6746474 Saadat Jun 2004 B2
6748953 Sherry et al. Jun 2004 B2
6749607 Edwards et al. Jun 2004 B2
6752805 Maguire et al. Jun 2004 B2
6760616 Hoey et al. Jul 2004 B2
6763261 Casscells, III et al. Jul 2004 B2
6764501 Ganz Jul 2004 B2
6769433 Zikorus et al. Aug 2004 B2
6770070 Balbierz Aug 2004 B1
6771996 Bowe et al. Aug 2004 B2
6773433 Stewart et al. Aug 2004 B2
6786900 Joye et al. Sep 2004 B2
6786901 Joye et al. Sep 2004 B2
6786904 Döscher et al. Sep 2004 B2
6788977 Fenn et al. Sep 2004 B2
6790206 Panescu Sep 2004 B2
6790222 Kugler et al. Sep 2004 B2
6796981 Wham et al. Sep 2004 B2
6797933 Mendis et al. Sep 2004 B1
6797960 Spartiotis et al. Sep 2004 B1
6800075 Mische et al. Oct 2004 B2
6802857 Walsh et al. Oct 2004 B1
6807444 Tu et al. Oct 2004 B2
6811550 Holland et al. Nov 2004 B2
6813520 Truckai et al. Nov 2004 B2
6814730 Li Nov 2004 B2
6814733 Schwartz et al. Nov 2004 B2
6823205 Jara Nov 2004 B1
6824516 Batten et al. Nov 2004 B2
6827726 Parodi Dec 2004 B2
6827926 Robinson et al. Dec 2004 B2
6829497 Mogul Dec 2004 B2
6830568 Kesten et al. Dec 2004 B1
6837886 Collins et al. Jan 2005 B2
6837888 Ciarrocca et al. Jan 2005 B2
6845267 Harrison Jan 2005 B2
6847848 Sterzer Jan 2005 B2
6849073 Hoey et al. Feb 2005 B2
6849075 Bertolero et al. Feb 2005 B2
6853425 Kim et al. Feb 2005 B2
6855123 Nita Feb 2005 B2
6855143 Davison Feb 2005 B2
6869431 Maguire et al. Mar 2005 B2
6872183 Sampson et al. Mar 2005 B2
6884260 Kugler et al. Apr 2005 B2
6889694 Hooven May 2005 B2
6893436 Woodard et al. May 2005 B2
6895077 Karellas et al. May 2005 B2
6895265 Silver May 2005 B2
6898454 Atalar et al. May 2005 B2
6899711 Stewart et al. May 2005 B2
6899718 Gifford, III et al. May 2005 B2
6905494 Yon et al. Jun 2005 B2
6908462 Joye et al. Jun 2005 B2
6909009 Koridze Jun 2005 B2
6911026 Hall et al. Jun 2005 B1
6915806 Pacek et al. Jul 2005 B2
6923805 LaFontaine et al. Aug 2005 B1
6923808 Taimisto Aug 2005 B2
6926246 Ginggen Aug 2005 B2
6926713 Rioux et al. Aug 2005 B2
6926716 Baker et al. Aug 2005 B2
6929009 Makower et al. Aug 2005 B2
6929632 Nita et al. Aug 2005 B2
6929639 Lafontaine Aug 2005 B2
6932776 Carr Aug 2005 B2
6936047 Nasab et al. Aug 2005 B2
6942620 Nita et al. Sep 2005 B2
6942657 Sinofsky et al. Sep 2005 B2
6942677 Nita et al. Sep 2005 B2
6942692 Landau et al. Sep 2005 B2
6949097 Stewart et al. Sep 2005 B2
6949121 Laguna Sep 2005 B1
6952615 Satake Oct 2005 B2
6953425 Brister Oct 2005 B2
6955174 Joye et al. Oct 2005 B2
6955175 Stevens et al. Oct 2005 B2
6959711 Murphy et al. Nov 2005 B2
6960207 Vanney et al. Nov 2005 B2
6962584 Stone et al. Nov 2005 B1
6964660 Maguire et al. Nov 2005 B2
6966908 Maguire et al. Nov 2005 B2
6972015 Joye et al. Dec 2005 B2
6972024 Kilpatrick et al. Dec 2005 B1
6974456 Edwards et al. Dec 2005 B2
6978174 Gelfand et al. Dec 2005 B2
6979329 Burnside et al. Dec 2005 B2
6979420 Weber Dec 2005 B2
6984238 Gifford, III et al. Jan 2006 B2
6985774 Kieval et al. Jan 2006 B2
6986739 Warren et al. Jan 2006 B2
6989009 Lafontaine Jan 2006 B2
6989010 Francischelli et al. Jan 2006 B2
6991617 Hektner et al. Jan 2006 B2
7001378 Yon et al. Feb 2006 B2
7006858 Silver et al. Feb 2006 B2
7022105 Edwards Apr 2006 B1
7022120 Lafontaine Apr 2006 B2
7025767 Schaefer et al. Apr 2006 B2
7033322 Silver Apr 2006 B2
7033372 Cahalan Apr 2006 B1
7041098 Farley et al. May 2006 B2
7050848 Hoey et al. May 2006 B2
7063670 Sampson et al. Jun 2006 B2
7063679 Maguire et al. Jun 2006 B2
7063719 Jansen et al. Jun 2006 B2
7066895 Podany Jun 2006 B2
7066900 Botto et al. Jun 2006 B2
7066904 Rosenthal et al. Jun 2006 B2
7072720 Puskas Jul 2006 B2
7074217 Strul et al. Jul 2006 B2
7081112 Joye et al. Jul 2006 B2
7081114 Rashidi Jul 2006 B2
7083614 Fjield et al. Aug 2006 B2
7084276 Vu et al. Aug 2006 B2
7087026 Callister et al. Aug 2006 B2
7087051 Bourne et al. Aug 2006 B2
7087052 Sampson et al. Aug 2006 B2
7087053 Vanney Aug 2006 B2
7089065 Westlund et al. Aug 2006 B2
7097641 Arless et al. Aug 2006 B1
7100614 Stevens et al. Sep 2006 B2
7101368 Lafontaine Sep 2006 B2
7104983 Grasso, III et al. Sep 2006 B2
7104987 Biggs et al. Sep 2006 B2
7108715 Lawrence-Brown et al. Sep 2006 B2
7112196 Brosch et al. Sep 2006 B2
7112198 Satake Sep 2006 B2
7112211 Gifford, III et al. Sep 2006 B2
7122019 Kesten et al. Oct 2006 B1
7122033 Wood Oct 2006 B2
7134438 Makower et al. Nov 2006 B2
7137963 Nita et al. Nov 2006 B2
7137980 Buysse et al. Nov 2006 B2
7153315 Miller Dec 2006 B2
7155271 Halperin et al. Dec 2006 B2
7157491 Mewshaw et al. Jan 2007 B2
7157492 Mewshaw et al. Jan 2007 B2
7158832 Kieval et al. Jan 2007 B2
7160296 Pearson et al. Jan 2007 B2
7162303 Levin et al. Jan 2007 B2
7165551 Edwards et al. Jan 2007 B2
7169144 Hoey et al. Jan 2007 B2
7172589 Lafontaine Feb 2007 B2
7172610 Heitzmann et al. Feb 2007 B2
7181261 Silver et al. Feb 2007 B2
7184811 Phan et al. Feb 2007 B2
7184827 Edwards Feb 2007 B1
7189227 Lafontaine Mar 2007 B2
7192427 Chapelon et al. Mar 2007 B2
7192586 Bander Mar 2007 B2
7197354 Sobe Mar 2007 B2
7198632 Lim et al. Apr 2007 B2
7200445 Dalbec et al. Apr 2007 B1
7201749 Govari et al. Apr 2007 B2
7203537 Mower Apr 2007 B2
7214234 Rapacki et al. May 2007 B2
7220233 Nita et al. May 2007 B2
7220239 Wilson et al. May 2007 B2
7220257 Lafontaine May 2007 B1
7220270 Sawhney et al. May 2007 B2
7232458 Saadat Jun 2007 B2
7232459 Greenberg et al. Jun 2007 B2
7238184 Megerman et al. Jul 2007 B2
7241273 Maguire et al. Jul 2007 B2
7241736 Hunter et al. Jul 2007 B2
7247141 Makin et al. Jul 2007 B2
7250041 Chiu et al. Jul 2007 B2
7250440 Mewshaw et al. Jul 2007 B2
7252664 Nasab et al. Aug 2007 B2
7252679 Fischell et al. Aug 2007 B2
7264619 Venturelli Sep 2007 B2
7279600 Mewshaw et al. Oct 2007 B2
7280863 Shachar Oct 2007 B2
7282213 Schroeder et al. Oct 2007 B2
7285119 Stewart et al. Oct 2007 B2
7285120 Im et al. Oct 2007 B2
7288089 Yon et al. Oct 2007 B2
7288096 Chin Oct 2007 B2
7291146 Steinke et al. Nov 2007 B2
7293562 Malecki et al. Nov 2007 B2
7294125 Phalen et al. Nov 2007 B2
7294126 Sampson et al. Nov 2007 B2
7294127 Leung et al. Nov 2007 B2
7297131 Nita Nov 2007 B2
7297475 Koiwai et al. Nov 2007 B2
7300433 Lane et al. Nov 2007 B2
7301108 Egitto et al. Nov 2007 B2
7310150 Guillermo et al. Dec 2007 B2
7313430 Urquhart et al. Dec 2007 B2
7314480 Eidenschink et al. Jan 2008 B2
7314483 Landau et al. Jan 2008 B2
7317077 Averback et al. Jan 2008 B2
7323006 Andreas et al. Jan 2008 B2
7326206 Paul et al. Feb 2008 B2
7326226 Root et al. Feb 2008 B2
7326235 Edwards Feb 2008 B2
7326237 DePalma et al. Feb 2008 B2
7329236 Kesten et al. Feb 2008 B2
7335180 Nita et al. Feb 2008 B2
7335192 Keren et al. Feb 2008 B2
7338467 Lutter Mar 2008 B2
7341570 Keren et al. Mar 2008 B2
7343195 Strommer et al. Mar 2008 B2
7347857 Anderson et al. Mar 2008 B2
7348003 Salcedo et al. Mar 2008 B2
7352593 Zeng et al. Apr 2008 B2
7354927 Vu Apr 2008 B2
7359732 Kim et al. Apr 2008 B2
7361341 Salcedo et al. Apr 2008 B2
7364566 Elkins et al. Apr 2008 B2
7367970 Govari et al. May 2008 B2
7367975 Malecki et al. May 2008 B2
7371231 Rioux et al. May 2008 B2
7387126 Cox et al. Jun 2008 B2
7393338 Nita Jul 2008 B2
7396355 Goldman et al. Jul 2008 B2
7402151 Rosenman et al. Jul 2008 B2
7402312 Rosen et al. Jul 2008 B2
7404824 Webler et al. Jul 2008 B1
7406970 Zikorus et al. Aug 2008 B2
7407502 Strul et al. Aug 2008 B2
7407506 Makower Aug 2008 B2
7407671 McBride et al. Aug 2008 B2
7408021 Averback et al. Aug 2008 B2
7410486 Fuimaono et al. Aug 2008 B2
7413556 Zhang et al. Aug 2008 B2
7425212 Danek et al. Sep 2008 B1
7426409 Casscells, III et al. Sep 2008 B2
7435248 Taimisto et al. Oct 2008 B2
7447453 Kim et al. Nov 2008 B2
7449018 Kramer Nov 2008 B2
7452538 Ni et al. Nov 2008 B2
7473890 Grier et al. Jan 2009 B2
7476384 Ni et al. Jan 2009 B2
7479157 Weber et al. Jan 2009 B2
7481803 Kesten et al. Jan 2009 B2
7485104 Kieval Feb 2009 B2
7486805 Krattiger Feb 2009 B2
7487780 Hooven Feb 2009 B2
7493154 Bonner et al. Feb 2009 B2
7494485 Beck et al. Feb 2009 B2
7494486 Mische et al. Feb 2009 B2
7494488 Weber Feb 2009 B2
7494661 Sanders Feb 2009 B2
7495439 Wiggins Feb 2009 B2
7497858 Chapelon et al. Mar 2009 B2
7499745 Littrup et al. Mar 2009 B2
7500985 Saadat Mar 2009 B2
7505812 Eggers et al. Mar 2009 B1
7505816 Schmeling et al. Mar 2009 B2
7507233 Littrup et al. Mar 2009 B2
7507235 Keogh et al. Mar 2009 B2
7511494 Wedeen Mar 2009 B2
7512445 Truckai et al. Mar 2009 B2
7527643 Case et al. May 2009 B2
7529589 Williams et al. May 2009 B2
7540852 Nita et al. Jun 2009 B2
7540870 Babaev Jun 2009 B2
RE40863 Tay et al. Jul 2009 E
7556624 Laufer et al. Jul 2009 B2
7558625 Levin et al. Jul 2009 B2
7563247 Maguire et al. Jul 2009 B2
7566319 McAuley et al. Jul 2009 B2
7569052 Phan et al. Aug 2009 B2
7582111 Krolik et al. Sep 2009 B2
7584004 Caparso et al. Sep 2009 B2
7585835 Hill et al. Sep 2009 B2
7591996 Hwang et al. Sep 2009 B2
7597704 Frazier et al. Oct 2009 B2
7598228 Hattori et al. Oct 2009 B2
7599730 Hunter et al. Oct 2009 B2
7603166 Casscells, III et al. Oct 2009 B2
7604608 Nita et al. Oct 2009 B2
7604633 Truckai et al. Oct 2009 B2
7615015 Coleman Nov 2009 B2
7615072 Rust et al. Nov 2009 B2
7617005 Demarais et al. Nov 2009 B2
7620451 Demarais et al. Nov 2009 B2
7621902 Nita et al. Nov 2009 B2
7621929 Nita et al. Nov 2009 B2
7626015 Feinstein et al. Dec 2009 B2
7626235 Kinoshita Dec 2009 B2
7632268 Edwards et al. Dec 2009 B2
7632845 Vu et al. Dec 2009 B2
7635383 Gumm Dec 2009 B2
7640046 Pastore et al. Dec 2009 B2
7641633 Laufer et al. Jan 2010 B2
7641679 Joye et al. Jan 2010 B2
7646544 Batchko et al. Jan 2010 B2
7647115 Levin et al. Jan 2010 B2
7653438 Deem et al. Jan 2010 B2
7655006 Sauvageau et al. Feb 2010 B2
7662114 Seip et al. Feb 2010 B2
7664548 Amurthur et al. Feb 2010 B2
7670279 Gertner Mar 2010 B2
7670335 Keidar Mar 2010 B2
7671084 Mewshaw et al. Mar 2010 B2
7678104 Keidar Mar 2010 B2
7678106 Lee Mar 2010 B2
7678108 Chrisitian et al. Mar 2010 B2
7686841 Eidenschink et al. Mar 2010 B2
7691080 Seward et al. Apr 2010 B2
7699809 Urmey Apr 2010 B2
7706882 Francischelli et al. Apr 2010 B2
7715912 Rezai et al. May 2010 B2
7717853 Nita May 2010 B2
7717909 Strul et al. May 2010 B2
7717948 Demarais et al. May 2010 B2
7722539 Carter et al. May 2010 B2
7725157 Dumoulin et al. May 2010 B2
7727178 Wilson et al. Jun 2010 B2
7736317 Stephens et al. Jun 2010 B2
7736360 Mody et al. Jun 2010 B2
7736362 Eberl et al. Jun 2010 B2
7738952 Yun et al. Jun 2010 B2
7740629 Anderson et al. Jun 2010 B2
7741299 Feinstein et al. Jun 2010 B2
7742795 Stone et al. Jun 2010 B2
7744594 Yamazaki et al. Jun 2010 B2
7753907 DiMatteo et al. Jul 2010 B2
7756583 Demarais et al. Jul 2010 B2
7758510 Nita et al. Jul 2010 B2
7758520 Griffin et al. Jul 2010 B2
7759315 Cuzzocrea et al. Jul 2010 B2
7766833 Lee et al. Aug 2010 B2
7766878 Tremaglio, Jr. et al. Aug 2010 B2
7766892 Keren et al. Aug 2010 B2
7767844 Lee et al. Aug 2010 B2
7769427 Shachar Aug 2010 B2
7771372 Wilson Aug 2010 B2
7771421 Stewart et al. Aug 2010 B2
7776967 Perry et al. Aug 2010 B2
7777486 Hargreaves et al. Aug 2010 B2
7780660 Bourne et al. Aug 2010 B2
7789876 Zikorus et al. Sep 2010 B2
7792568 Zhong et al. Sep 2010 B2
7799021 Leung et al. Sep 2010 B2
7803168 Gifford et al. Sep 2010 B2
7806871 Li et al. Oct 2010 B2
7811265 Hering et al. Oct 2010 B2
7811281 Rentrop Oct 2010 B1
7811313 Mon et al. Oct 2010 B2
7816511 Kawashima et al. Oct 2010 B2
7818053 Kassab Oct 2010 B2
7819866 Bednarek Oct 2010 B2
7822460 Halperin et al. Oct 2010 B2
7828837 Khoury Nov 2010 B2
7832407 Gertner Nov 2010 B2
7833220 Mon et al. Nov 2010 B2
7837676 Sinelnikov et al. Nov 2010 B2
7837720 Mon Nov 2010 B2
7841978 Gertner Nov 2010 B2
7846157 Kozel Dec 2010 B2
7846160 Payne et al. Dec 2010 B2
7846172 Makower Dec 2010 B2
7849860 Makower et al. Dec 2010 B2
7850685 Kunis et al. Dec 2010 B2
7853333 Demarais Dec 2010 B2
7854734 Biggs et al. Dec 2010 B2
7857756 Warren et al. Dec 2010 B2
7862565 Eder et al. Jan 2011 B2
7863897 Slocum, Jr. et al. Jan 2011 B2
7869854 Shachar et al. Jan 2011 B2
7873417 Demarais et al. Jan 2011 B2
7887538 Bleich et al. Feb 2011 B2
7894905 Pless et al. Feb 2011 B2
7896873 Hiller et al. Mar 2011 B2
7901400 Wham et al. Mar 2011 B2
7901402 Jones et al. Mar 2011 B2
7901420 Dunn Mar 2011 B2
7905862 Sampson Mar 2011 B2
7918850 Govari et al. Apr 2011 B2
7927370 Webler et al. Apr 2011 B2
7937143 Demarais et al. May 2011 B2
7938830 Saadat et al. May 2011 B2
7942874 Eder et al. May 2011 B2
7942928 Webler et al. May 2011 B2
7946976 Gertner May 2011 B2
7950397 Thapliyal et al. May 2011 B2
7955293 Nita et al. Jun 2011 B2
7956613 Wald Jun 2011 B2
7959627 Utley et al. Jun 2011 B2
7962854 Vance et al. Jun 2011 B2
7967782 Laufer et al. Jun 2011 B2
7967808 Fitzgerald et al. Jun 2011 B2
7972327 Eberl et al. Jul 2011 B2
7972330 Alejandro et al. Jul 2011 B2
7983751 Zdeblick et al. Jul 2011 B2
8001976 Gertner Aug 2011 B2
8007440 Magnin et al. Aug 2011 B2
8012147 Lafontaine Sep 2011 B2
8019435 Hastings et al. Sep 2011 B2
8021362 Deem et al. Sep 2011 B2
8021413 Dierking et al. Sep 2011 B2
8025661 Arnold et al. Sep 2011 B2
8027718 Spinner et al. Sep 2011 B2
8031927 Karl et al. Oct 2011 B2
8033284 Porter et al. Oct 2011 B2
8043673 Lee et al. Oct 2011 B2
8048144 Thistle et al. Nov 2011 B2
8052636 Moll et al. Nov 2011 B2
8052700 Dunn Nov 2011 B2
8062289 Babaev Nov 2011 B2
8075580 Makower Dec 2011 B2
8080006 Lafontaine et al. Dec 2011 B2
8088127 Mayse et al. Jan 2012 B2
8116883 Williams et al. Feb 2012 B2
8119183 O'Donoghue et al. Feb 2012 B2
8120518 Jang et al. Feb 2012 B2
8123741 Marrouche et al. Feb 2012 B2
8128617 Bencini et al. Mar 2012 B2
8131371 Demarals et al. Mar 2012 B2
8131372 Levin et al. Mar 2012 B2
8131382 Asada Mar 2012 B2
8137274 Weng et al. Mar 2012 B2
8140170 Rezai et al. Mar 2012 B2
8143316 Ueno Mar 2012 B2
8145316 Deem et al. Mar 2012 B2
8145317 Demarais et al. Mar 2012 B2
8150518 Levin et al. Apr 2012 B2
8150519 Demarais et al. Apr 2012 B2
8150520 Demarais et al. Apr 2012 B2
8152830 Gumm Apr 2012 B2
8162933 Francischelli et al. Apr 2012 B2
8168275 Lee et al. May 2012 B2
8175711 Demarais et al. May 2012 B2
8187261 Watson May 2012 B2
8190238 Moll et al. May 2012 B2
8192053 Owen et al. Jun 2012 B2
8198611 LaFontaine et al. Jun 2012 B2
8214056 Hoffer et al. Jul 2012 B2
8221407 Phan et al. Jul 2012 B2
8226637 Satake Jul 2012 B2
8231617 Satake Jul 2012 B2
8241217 Chiang et al. Aug 2012 B2
8257724 Cromack et al. Sep 2012 B2
8257725 Cromack et al. Sep 2012 B2
8260397 Ruff et al. Sep 2012 B2
8263104 Ho et al. Sep 2012 B2
8273023 Razavi Sep 2012 B2
8277379 Lau et al. Oct 2012 B2
8287524 Siegel Oct 2012 B2
8287532 Carroll et al. Oct 2012 B2
8292881 Brannan et al. Oct 2012 B2
8293703 Averback et al. Oct 2012 B2
8295902 Salahieh et al. Oct 2012 B2
8295912 Gertner Oct 2012 B2
8308722 Ormsby et al. Nov 2012 B2
8317776 Ferren et al. Nov 2012 B2
8317810 Stangenes et al. Nov 2012 B2
8329179 Ni et al. Dec 2012 B2
8336705 Okahisa Dec 2012 B2
8343031 Gertner Jan 2013 B2
8343145 Brannan Jan 2013 B2
8347891 Demarais et al. Jan 2013 B2
8353945 Andreas et al. Jan 2013 B2
8364237 Stone et al. Jan 2013 B2
8366615 Razavi Feb 2013 B2
8382697 Brenneman et al. Feb 2013 B2
8388680 Starksen et al. Mar 2013 B2
8396548 Perry et al. Mar 2013 B2
8398629 Thistle Mar 2013 B2
8401667 Gustus et al. Mar 2013 B2
8403881 Ferren et al. Mar 2013 B2
8406877 Smith et al. Mar 2013 B2
8409172 Moll et al. Apr 2013 B2
8409193 Young et al. Apr 2013 B2
8409195 Young Apr 2013 B2
8418362 Zerfas et al. Apr 2013 B2
8452988 Wang May 2013 B2
8454594 Demarais et al. Jun 2013 B2
8460358 Andreas et al. Jun 2013 B2
8465452 Kassab Jun 2013 B2
8469919 Ingle et al. Jun 2013 B2
8473067 Hastings et al. Jun 2013 B2
8480663 Ingle et al. Jul 2013 B2
8485992 Griffin et al. Jul 2013 B2
8486060 Kotmel et al. Jul 2013 B2
8486063 Werneth et al. Jul 2013 B2
8488591 Miali et al. Jul 2013 B2
20010007070 Stewart et al. Jul 2001 A1
20010039419 Francischelli et al. Nov 2001 A1
20020022864 Mahvi et al. Feb 2002 A1
20020042639 Murphy-Chutorian et al. Apr 2002 A1
20020045811 Kittrell et al. Apr 2002 A1
20020045890 Celliers et al. Apr 2002 A1
20020062146 Makower et al. May 2002 A1
20020065542 Lax et al. May 2002 A1
20020087151 Mody et al. Jul 2002 A1
20020095197 Lardo et al. Jul 2002 A1
20020107536 Hussein Aug 2002 A1
20020147480 Mamayek Oct 2002 A1
20020169444 Mest et al. Nov 2002 A1
20020198520 Coen et al. Dec 2002 A1
20030050635 Truckai et al. Mar 2003 A1
20030065317 Rudie et al. Apr 2003 A1
20030092995 Thompson May 2003 A1
20030139689 Shturman et al. Jul 2003 A1
20030195501 Sherman et al. Oct 2003 A1
20030199747 Michlitsch et al. Oct 2003 A1
20030229340 Sherry et al. Dec 2003 A1
20030233099 Danaek et al. Dec 2003 A1
20040010118 Zerhusen et al. Jan 2004 A1
20040019348 Stevens et al. Jan 2004 A1
20040024371 Plicchi et al. Feb 2004 A1
20040043030 Griffiths et al. Mar 2004 A1
20040064090 Keren et al. Apr 2004 A1
20040073206 Foley et al. Apr 2004 A1
20040088002 Boyle et al. May 2004 A1
20040093055 Bartorelli et al. May 2004 A1
20040106871 Hunyor et al. Jun 2004 A1
20040117032 Roth Jun 2004 A1
20040147915 Hasebe Jul 2004 A1
20040162555 Farley et al. Aug 2004 A1
20040167506 Chen Aug 2004 A1
20040186356 O'Malley et al. Sep 2004 A1
20040187875 He et al. Sep 2004 A1
20040193211 Voegele et al. Sep 2004 A1
20040220556 Cooper et al. Nov 2004 A1
20040243022 Carney et al. Dec 2004 A1
20040253304 Gross et al. Dec 2004 A1
20040267250 Yon et al. Dec 2004 A1
20050010095 Stewart et al. Jan 2005 A1
20050015125 Mioduski et al. Jan 2005 A1
20050080374 Esch et al. Apr 2005 A1
20050096647 Steinke et al. May 2005 A1
20050129616 Salcedo et al. Jun 2005 A1
20050137180 Robinson et al. Jun 2005 A1
20050143817 Hunter et al. Jun 2005 A1
20050148842 Wang et al. Jul 2005 A1
20050149069 Bertolero et al. Jul 2005 A1
20050149080 Hunter et al. Jul 2005 A1
20050149158 Hunter et al. Jul 2005 A1
20050149173 Hunter et al. Jul 2005 A1
20050149175 Hunter et al. Jul 2005 A1
20050154277 Tang et al. Jul 2005 A1
20050154445 Hunter et al. Jul 2005 A1
20050154453 Hunter et al. Jul 2005 A1
20050154454 Hunter et al. Jul 2005 A1
20050165389 Swain et al. Jul 2005 A1
20050165391 Maguire et al. Jul 2005 A1
20050165467 Hunter et al. Jul 2005 A1
20050165488 Hunter et al. Jul 2005 A1
20050171597 Boatman et al. Aug 2005 A1
20050175661 Hunter et al. Aug 2005 A1
20050175662 Hunter et al. Aug 2005 A1
20050175663 Hunter et al. Aug 2005 A1
20050177103 Hunter et al. Aug 2005 A1
20050177225 Hunter et al. Aug 2005 A1
20050181004 Hunter et al. Aug 2005 A1
20050181008 Hunter et al. Aug 2005 A1
20050181011 Hunter et al. Aug 2005 A1
20050181977 Hunter et al. Aug 2005 A1
20050182479 Bonsignore et al. Aug 2005 A1
20050183728 Hunter et al. Aug 2005 A1
20050186242 Hunter et al. Aug 2005 A1
20050186243 Hunter et al. Aug 2005 A1
20050191331 Hunter et al. Sep 2005 A1
20050203410 Jenkins Sep 2005 A1
20050209587 Joye et al. Sep 2005 A1
20050214205 Salcedo et al. Sep 2005 A1
20050214207 Salcedo et al. Sep 2005 A1
20050214208 Salcedo et al. Sep 2005 A1
20050214209 Salcedo et al. Sep 2005 A1
20050214210 Salcedo et al. Sep 2005 A1
20050214268 Cavanagh et al. Sep 2005 A1
20050228286 Messerly et al. Oct 2005 A1
20050228415 Gertner Oct 2005 A1
20050228459 Levin et al. Oct 2005 A1
20050228460 Levin et al. Oct 2005 A1
20050232921 Rosen et al. Oct 2005 A1
20050234312 Suzuki et al. Oct 2005 A1
20050245862 Seward Nov 2005 A1
20050251116 Steinke et al. Nov 2005 A1
20050252553 Ginggen Nov 2005 A1
20050256398 Hastings et al. Nov 2005 A1
20050267556 Shuros et al. Dec 2005 A1
20050273149 Tran et al. Dec 2005 A1
20060004323 Chang et al. Jan 2006 A1
20060018949 Ammon et al. Jan 2006 A1
20060024564 Manclaw Feb 2006 A1
20060025765 Landman et al. Feb 2006 A1
20060062786 Salcedo et al. Mar 2006 A1
20060083194 Dhrimaj et al. Apr 2006 A1
20060085054 Zikorus et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060089638 Carmel et al. Apr 2006 A1
20060095096 DeBenedictis et al. May 2006 A1
20060106375 Werneth et al. May 2006 A1
20060142790 Gertner Jun 2006 A1
20060147492 Hunter et al. Jul 2006 A1
20060167106 Zhang et al. Jul 2006 A1
20060167498 DiLorenzo Jul 2006 A1
20060171895 Bucay-Couto Aug 2006 A1
20060182873 Klisch et al. Aug 2006 A1
20060184221 Stewart et al. Aug 2006 A1
20060195139 Gertner Aug 2006 A1
20060206150 Demarais et al. Sep 2006 A1
20060224153 Fischell et al. Oct 2006 A1
20060239921 Mangat et al. Oct 2006 A1
20060240070 Cromack et al. Oct 2006 A1
20060247266 Yamada et al. Nov 2006 A1
20060247760 Ganesan et al. Nov 2006 A1
20060263393 Demopulos et al. Nov 2006 A1
20060269555 Salcedo et al. Nov 2006 A1
20060271111 Demarais et al. Nov 2006 A1
20060287644 Inganas et al. Dec 2006 A1
20070016184 Cropper et al. Jan 2007 A1
20070016274 Boveja et al. Jan 2007 A1
20070027390 Maschke et al. Feb 2007 A1
20070043077 Mewshaw et al. Feb 2007 A1
20070043409 Brian et al. Feb 2007 A1
20070049924 Rahn Mar 2007 A1
20070066972 Ormsby et al. Mar 2007 A1
20070067883 Sretavan Mar 2007 A1
20070073151 Lee Mar 2007 A1
20070093710 Maschke Apr 2007 A1
20070100405 Thompson et al. May 2007 A1
20070106247 Burnett et al. May 2007 A1
20070112327 Yun et al. May 2007 A1
20070118107 Francischelli et al. May 2007 A1
20070129720 Demarais et al. Jun 2007 A1
20070129760 Demarais et al. Jun 2007 A1
20070129761 Demarais et al. Jun 2007 A1
20070135875 Demarais et al. Jun 2007 A1
20070149963 Matsukuma et al. Jun 2007 A1
20070162109 Davila et al. Jul 2007 A1
20070173805 Weinberg et al. Jul 2007 A1
20070179496 Swoyer et al. Aug 2007 A1
20070203480 Mody et al. Aug 2007 A1
20070207186 Scanlon et al. Sep 2007 A1
20070208134 Hunter et al. Sep 2007 A1
20070208210 Gelfand et al. Sep 2007 A1
20070208256 Marilla Sep 2007 A1
20070208301 Evard et al. Sep 2007 A1
20070219576 Cangialosi Sep 2007 A1
20070225781 Saadat et al. Sep 2007 A1
20070233170 Gertner Oct 2007 A1
20070239062 Chopra et al. Oct 2007 A1
20070248639 Demopulos et al. Oct 2007 A1
20070249703 Mewshaw et al. Oct 2007 A1
20070254833 Hunter et al. Nov 2007 A1
20070265687 Deem et al. Nov 2007 A1
20070278103 Hoerr et al. Dec 2007 A1
20070282302 Wachsman et al. Dec 2007 A1
20070292411 Salcedo et al. Dec 2007 A1
20070293782 Marino Dec 2007 A1
20070299043 Hunter et al. Dec 2007 A1
20080004673 Rossing et al. Jan 2008 A1
20080009927 Vilims Jan 2008 A1
20080015501 Gertner Jan 2008 A1
20080021408 Jacobsen et al. Jan 2008 A1
20080033049 Mewshaw Feb 2008 A1
20080039746 Hissong et al. Feb 2008 A1
20080039830 Munger et al. Feb 2008 A1
20080051454 Wang Feb 2008 A1
20080064957 Spence Mar 2008 A1
20080071269 Hilario et al. Mar 2008 A1
20080071306 Gertner Mar 2008 A1
20080082109 Moll et al. Apr 2008 A1
20080086072 Bonutti et al. Apr 2008 A1
20080091193 Kauphusman et al. Apr 2008 A1
20080097251 Babaev Apr 2008 A1
20080097426 Root et al. Apr 2008 A1
20080108867 Zhou May 2008 A1
20080119879 Brenneman et al. May 2008 A1
20080125772 Stone et al. May 2008 A1
20080132450 Lee et al. Jun 2008 A1
20080140002 Ramzipoor et al. Jun 2008 A1
20080147002 Gertner Jun 2008 A1
20080161662 Golijanin et al. Jul 2008 A1
20080161717 Gertner Jul 2008 A1
20080161801 Steinke et al. Jul 2008 A1
20080171974 Lafontaine et al. Jul 2008 A1
20080172035 Starksen et al. Jul 2008 A1
20080172104 Kieval et al. Jul 2008 A1
20080183259 Bly et al. Jul 2008 A1
20080188912 Stone et al. Aug 2008 A1
20080188913 Stone et al. Aug 2008 A1
20080208162 Joshi Aug 2008 A1
20080208169 Boyle et al. Aug 2008 A1
20080213331 Gelfand et al. Sep 2008 A1
20080215117 Gross Sep 2008 A1
20080221448 Khuri-Yakub et al. Sep 2008 A1
20080234790 Bayer et al. Sep 2008 A1
20080243091 Humphreys et al. Oct 2008 A1
20080245371 Gruber Oct 2008 A1
20080249525 Lee et al. Oct 2008 A1
20080249547 Dunn Oct 2008 A1
20080255550 Bell Oct 2008 A1
20080255642 Zarins et al. Oct 2008 A1
20080262489 Steinke Oct 2008 A1
20080275484 Gertner Nov 2008 A1
20080281312 Werneth et al. Nov 2008 A1
20080281347 Gertner Nov 2008 A1
20080287918 Rosenman et al. Nov 2008 A1
20080294037 Richter Nov 2008 A1
20080300618 Gertner Dec 2008 A1
20080312644 Fourkas et al. Dec 2008 A1
20080312673 Viswanathan et al. Dec 2008 A1
20080317818 Griffith et al. Dec 2008 A1
20090018486 Goren et al. Jan 2009 A1
20090018609 DiLorenzo Jan 2009 A1
20090024194 Arcot-Krishnamurthy et al. Jan 2009 A1
20090030312 Hadjicostis Jan 2009 A1
20090036948 Levin et al. Feb 2009 A1
20090043372 Northrop et al. Feb 2009 A1
20090054082 Kim et al. Feb 2009 A1
20090062873 Wu et al. Mar 2009 A1
20090069671 Anderson Mar 2009 A1
20090076409 Wu et al. Mar 2009 A1
20090088735 Abboud et al. Apr 2009 A1
20090105631 Kieval Apr 2009 A1
20090112202 Young Apr 2009 A1
20090118620 Tgavalekos et al. May 2009 A1
20090118726 Auth et al. May 2009 A1
20090125099 Weber et al. May 2009 A1
20090131798 Minar et al. May 2009 A1
20090143640 Saadat et al. Jun 2009 A1
20090156988 Ferren et al. Jun 2009 A1
20090157057 Ferren et al. Jun 2009 A1
20090157161 Desai et al. Jun 2009 A1
20090171333 Hon Jul 2009 A1
20090192558 Whitehurst et al. Jul 2009 A1
20090198223 Thilwind et al. Aug 2009 A1
20090203962 Miller et al. Aug 2009 A1
20090203993 Mangat et al. Aug 2009 A1
20090204170 Hastings et al. Aug 2009 A1
20090210953 Moyer et al. Aug 2009 A1
20090216317 Cromack et al. Aug 2009 A1
20090221955 Babaev Sep 2009 A1
20090226429 Salcedo et al. Sep 2009 A1
20090240249 Chan et al. Sep 2009 A1
20090247933 Maor et al. Oct 2009 A1
20090247966 Gunn et al. Oct 2009 A1
20090248012 Maor et al. Oct 2009 A1
20090253974 Rahme Oct 2009 A1
20090264755 Chen et al. Oct 2009 A1
20090270850 Zhou et al. Oct 2009 A1
20090281533 Ingle et al. Nov 2009 A1
20090287137 Crowley Nov 2009 A1
20090318749 Stolen et al. Dec 2009 A1
20100009267 Chase et al. Jan 2010 A1
20100030061 Canfield et al. Feb 2010 A1
20100048983 Ball et al. Feb 2010 A1
20100049099 Thapliyal et al. Feb 2010 A1
20100049186 Ingle et al. Feb 2010 A1
20100049188 Nelson et al. Feb 2010 A1
20100049191 Habib et al. Feb 2010 A1
20100049283 Johnson Feb 2010 A1
20100069837 Rassat et al. Mar 2010 A1
20100076299 Gustus et al. Mar 2010 A1
20100076425 Carroux Mar 2010 A1
20100087782 Ghaffari et al. Apr 2010 A1
20100106005 Karczmar et al. Apr 2010 A1
20100114244 Manda et al. May 2010 A1
20100130836 Malchano et al. May 2010 A1
20100137860 Demarais et al. Jun 2010 A1
20100137952 Demarais et al. Jun 2010 A1
20100160903 Krespi Jun 2010 A1
20100160906 Jarrard Jun 2010 A1
20100168624 Sliwa Jul 2010 A1
20100168731 Wu et al. Jul 2010 A1
20100168739 Wu et al. Jul 2010 A1
20100174282 Demarais et al. Jul 2010 A1
20100191112 Demarais et al. Jul 2010 A1
20100191232 Boveda Jul 2010 A1
20100217162 Hissong et al. Aug 2010 A1
20100222786 Kassab Sep 2010 A1
20100222851 Deem et al. Sep 2010 A1
20100222854 Demarais et al. Sep 2010 A1
20100228122 Keenan et al. Sep 2010 A1
20100249604 Hastings et al. Sep 2010 A1
20100249773 Clark et al. Sep 2010 A1
20100256616 Katoh et al. Oct 2010 A1
20100268217 Habib Oct 2010 A1
20100268307 Demarais et al. Oct 2010 A1
20100284927 Lu et al. Nov 2010 A1
20100286684 Hata et al. Nov 2010 A1
20100298821 Garbagnati Nov 2010 A1
20100305036 Barnes et al. Dec 2010 A1
20100312141 Keast et al. Dec 2010 A1
20100324472 Wulfman Dec 2010 A1
20110009750 Taylor et al. Jan 2011 A1
20110021976 Li et al. Jan 2011 A1
20110034832 Cioanta et al. Feb 2011 A1
20110040324 McCarthy et al. Feb 2011 A1
20110044942 Puri et al. Feb 2011 A1
20110060324 Wu et al. Mar 2011 A1
20110071400 Hastings et al. Mar 2011 A1
20110071401 Hastings et al. Mar 2011 A1
20110077498 McDaniel Mar 2011 A1
20110092781 Gertner Apr 2011 A1
20110092880 Gertner Apr 2011 A1
20110104061 Seward May 2011 A1
20110112400 Emery et al. May 2011 A1
20110118600 Gertner May 2011 A1
20110118726 De La Rama et al. May 2011 A1
20110130708 Perry et al. Jun 2011 A1
20110137155 Weber et al. Jun 2011 A1
20110144479 Hastings et al. Jun 2011 A1
20110146673 Keast et al. Jun 2011 A1
20110166499 Demarais et al. Jul 2011 A1
20110178570 Demarais Jul 2011 A1
20110200171 Beetel et al. Aug 2011 A1
20110202098 Demarais et al. Aug 2011 A1
20110207758 Sobotka et al. Aug 2011 A1
20110208096 Demarais et al. Aug 2011 A1
20110257523 Hastings et al. Oct 2011 A1
20110257564 Demarais et al. Oct 2011 A1
20110257622 Salahieh et al. Oct 2011 A1
20110257641 Hastings et al. Oct 2011 A1
20110257642 Griggs, III Oct 2011 A1
20110263921 Vrba et al. Oct 2011 A1
20110264011 Wu et al. Oct 2011 A1
20110264075 Leung et al. Oct 2011 A1
20110264086 Ingle Oct 2011 A1
20110264116 Kocur et al. Oct 2011 A1
20110270238 Rizq et al. Nov 2011 A1
20110306851 Wang Dec 2011 A1
20110319809 Smith Dec 2011 A1
20120029496 Smith Feb 2012 A1
20120029500 Jenson Feb 2012 A1
20120029505 Jenson Feb 2012 A1
20120029509 Smith Feb 2012 A1
20120029510 Haverkost Feb 2012 A1
20120029511 Smith et al. Feb 2012 A1
20120029512 Willard et al. Feb 2012 A1
20120029513 Smith et al. Feb 2012 A1
20120059241 Hastings et al. Mar 2012 A1
20120059286 Hastings et al. Mar 2012 A1
20120065506 Smith Mar 2012 A1
20120065554 Pikus Mar 2012 A1
20120095461 Herscher et al. Apr 2012 A1
20120101413 Beetel et al. Apr 2012 A1
20120101490 Smith Apr 2012 A1
20120101538 Ballakur et al. Apr 2012 A1
20120109021 Hastings et al. May 2012 A1
20120116382 Ku et al. May 2012 A1
20120116383 Mauch et al. May 2012 A1
20120116392 Willard May 2012 A1
20120116438 Salahieh et al. May 2012 A1
20120116486 Naga et al. May 2012 A1
20120123243 Hastings May 2012 A1
20120123258 Willard May 2012 A1
20120123261 Jenson et al. May 2012 A1
20120123303 Sogard et al. May 2012 A1
20120123406 Edmunds et al. May 2012 A1
20120130289 Demarais et al. May 2012 A1
20120130345 Levin et al. May 2012 A1
20120130359 Turovskiy May 2012 A1
20120130360 Buckley et al. May 2012 A1
20120130362 Hastings et al. May 2012 A1
20120130368 Jenson May 2012 A1
20120130458 Ryba et al. May 2012 A1
20120136344 Buckley et al. May 2012 A1
20120136349 Hastings May 2012 A1
20120136350 Goshgarian et al. May 2012 A1
20120136417 Buckley et al. May 2012 A1
20120136418 Buckley et al. May 2012 A1
20120143181 Demarais et al. Jun 2012 A1
20120143293 Mauch et al. Jun 2012 A1
20120143294 Clark et al. Jun 2012 A1
20120150267 Buckley et al. Jun 2012 A1
20120157986 Stone et al. Jun 2012 A1
20120157987 Steinke et al. Jun 2012 A1
20120157988 Stone et al. Jun 2012 A1
20120157989 Stone et al. Jun 2012 A1
20120157992 Smith et al. Jun 2012 A1
20120157993 Jenson et al. Jun 2012 A1
20120158101 Stone et al. Jun 2012 A1
20120158104 Huynh et al. Jun 2012 A1
20120172837 Demarais et al. Jul 2012 A1
20120172870 Jenson et al. Jul 2012 A1
20120184952 Jenson et al. Jul 2012 A1
20120197198 Demarais et al. Aug 2012 A1
20120197252 Deem et al. Aug 2012 A1
20120232409 Stahmann et al. Sep 2012 A1
20120265066 Crow et al. Oct 2012 A1
20120265198 Crow et al. Oct 2012 A1
20130012844 Demarais et al. Jan 2013 A1
20130012866 Deem et al. Jan 2013 A1
20130012867 Demarais et al. Jan 2013 A1
20130013024 Levin et al. Jan 2013 A1
20130023865 Steinke et al. Jan 2013 A1
20130035681 Subramaniam et al. Feb 2013 A1
20130066316 Steinke et al. Mar 2013 A1
20130085489 Fain et al. Apr 2013 A1
20130090563 Weber Apr 2013 A1
20130090578 Smith et al. Apr 2013 A1
20130090647 Smith Apr 2013 A1
20130090649 Smith et al. Apr 2013 A1
20130090650 Jenson et al. Apr 2013 A1
20130090651 Smith Apr 2013 A1
20130090652 Jenson Apr 2013 A1
20130096550 Hill Apr 2013 A1
20130096553 Hill et al. Apr 2013 A1
20130096554 Groff et al. Apr 2013 A1
20130096604 Hanson et al. Apr 2013 A1
20130110106 Richardson May 2013 A1
20130116687 Willard May 2013 A1
20130165764 Scheuermann et al. Jun 2013 A1
20130165844 Shuros et al. Jun 2013 A1
20130165916 Mathur et al. Jun 2013 A1
20130165917 Mathur et al. Jun 2013 A1
20130165920 Weber et al. Jun 2013 A1
20130165923 Mathur et al. Jun 2013 A1
20130165924 Mathur et al. Jun 2013 A1
20130165925 Mathur et al. Jun 2013 A1
20130165926 Mathur et al. Jun 2013 A1
20130165990 Mathur et al. Jun 2013 A1
20130172815 Perry et al. Jul 2013 A1
20130172872 Subramaniam et al. Jul 2013 A1
20130172877 Subramaniam et al. Jul 2013 A1
20130172878 Smith Jul 2013 A1
20130172879 Sutermeister Jul 2013 A1
20130172880 Willard Jul 2013 A1
20130172881 Hill et al. Jul 2013 A1
20140074083 Horn et al. Mar 2014 A1
Foreign Referenced Citations (44)
Number Date Country
10038737 Feb 2002 DE
1053720 Nov 2000 EP
1180004 Feb 2002 EP
1335677 Aug 2003 EP
1874211 Jan 2008 EP
1906853 Apr 2008 EP
1961394 Aug 2008 EP
1620156 Jul 2009 EP
2076193 Jul 2009 EP
2091455 Aug 2009 EP
2197533 Jun 2010 EP
2208506 Jul 2010 EP
1579889 Aug 2010 EP
2092957 Jan 2011 EP
2349044 Aug 2011 EP
2027882 Oct 2011 EP
2378956 Oct 2011 EP
2037840 Dec 2011 EP
2204134 Apr 2012 EP
2320821 Oct 2012 EP
2456301 Jul 2009 GB
9858588 Dec 1998 WO
9900060 Jan 1999 WO
9935986 Jul 1999 WO
0047118 Aug 2000 WO
0066021 Nov 2000 WO
0195820 Dec 2001 WO
03026525 Apr 2003 WO
2004100813 Nov 2004 WO
2004110258 Dec 2004 WO
2005041810 May 2005 WO
2006105121 Oct 2006 WO
2008014465 Jan 2008 WO
2009121017 Oct 2009 WO
2010067360 Jun 2010 WO
2010102310 Sep 2010 WO
2010132703 Nov 2010 WO
2011005901 Jan 2011 WO
2011053757 May 2011 WO
2011053772 May 2011 WO
2011091069 Jul 2011 WO
2011130534 Oct 2011 WO
2012019156 Feb 2012 WO
2013049601 Apr 2013 WO
Non-Patent Literature Citations (68)
Entry
US 8,398,630, 03/2013, Demarais et al. (withdrawn)
Van Den Berg, “Light echoes image the human body,” OLE, p. 35-37, Oct. 2001.
“IntraLuminal: Products,” IntraLuminal Therapeutics, Inc., p. 1-9, 2003.
“Laser Catheter to Aid Coronary Surgery,” TechTalk: MIT, p. 1-4, Jan. 9, 1991.
“Optical Coherence Tomography: LightLab Imaging Starts US Cardiology Clinical Investigations,” LightLab Imaging Technology Company Press Release, Jun. 25, 2002, <http://www.lightlabimaging.com/press/cardtrails.html> 2 pages.
“Optical Coherence Tomography: LightLab Sees Bright Prospects for Cardiac Application of OCT Technology,” LightLab Imaging Technology, The Gray Sheet, Medical Devices, Diagnostics, & Instrumentation, 27(35), Aug. 27, 2001, <http://www.lightlabimaging.com/press/graysheet.html> 1 page.
“Products—Functional Measurement,” Volcano Functional Measurement Products US, p. 1-2, Mar. 24, 2003.
Brown et al., “Radiofrequency capacitive heaters: the effect of coupling medium resistivity on power absorption along a mouse leg,” Physics in Medicine and Biology, 38: 1-12, 1993.
Carrington, “Future of CVI: It's all about plaque: Identification of vulnerable lesions, not ‘rusty pipes,’ could become cornerstone of preventive cardiology,” Diagnostic Imaging Special Edition Forum, 5 pages total, retrieved on Sep. 3, 2003.
Chen et al., “Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo,” EuroIntervention, p. 1-8, 2013.
Cimino, “Preventing plaque attack,” Mass High Tech, 3 pages total, retrieved on Sep. 3, 2003 <http://Masshightech.com/displayarticledetail.ap?art—id=52283&cat—id=10>, 2001.
Dahm et al., “Relation of Degree of Laser Debulking of In-Stent Restenosis as a Predictor of Restenosis Rate,” The American Journal of Cardiology, 90:68-70, 2002.
De Korte et al., “Characterization of Plaque Components With Intravascular Ultrasound Elastography in Human Femoral and Coronary Arteries In Vitro,” Circulation, Aug. 8, 2000, p. 617-623.
Durney et al., “Radiofrequency Radiation Dosimetry Handbook,” 7 pages, Fourth Edition, Oct. 1986.
Pieper et al. “Design and implementation of a new computerized system for intraoperative cardiac mapping”, J. Appl. Physiol. 71(4): 1529-1539, 1991.
Fournier-Desseux et al., “Assessment of 1-lead and 2-lead electrode patterns in electrical impedance endotomography,” Physiological Measurement, Institute of Physics Publishing, 26:337-349, 2005.
Fram et al., “Feasibility of Radiofrequency Powered, Thermal Balloon Ablation of Atrioventricular Bypass Tracts Via the Coronary Sinus: In Vivo Canine Studies,” PACE, 18:1518-1530, Aug. 1995.
Fram et al., “Low Pressure Radiofrequency Balloon Angioplasty: Evaluation in Porcine Peripheral Arteries,” JACC, American College of Cardiology, 21(6):1512-1521, 1993.
Fujimori et al., “Significant Prevention of In-Stent Restenosis by Evans Blue in Patients with Acute Myocardial Infarction,” American Heart Association, 2002.
Fujita et al., “Sarpogrelate, An Antagonist of 5-HT(2A) Receptor, Treatment Reduces Restenosis After Coronary Stenting,” American Heart Association, 2002.
Gabriel, “Appendix A: Experimental Data,” p. 1-21, 1999.
Gabriel, “Appendix C: Modeling the frequency dependence of the dielectric properties to a 4 dispersions spectrum,” p. 1-49, Nov. 6, 1997.
Gregory et al., “Liquid Core Light Guide for Laser Angioplasty,” The Journal of Quantum Electronics, 26 (12):2289-2296, Dec. 1990.
Kaplan et al., “Healing after Arterial Dilatation with Radiofrequency Thermal and Nonthermal Balloon Angioplasty Sytems,” Journal of Investigative Surgery, 6:33-52, 1993.
Kolata, “New Studies Question Value of Opening Arteries,” The New York Times [online], 5 pages total, <http://nytimes.com/2004/03/21/health/21HEAR.html?ei=5070&en=641bc03214e&ex=11067>, Mar. 21, 2004.
Konings et al., “Development of an Intravascular Impedance Catheter for Detection of Fatty Lesions in Arteries,” IEEE Transactions on Medical Imaging, 16(4):439-444, Aug. 1997.
Kurtz et al., “Lamellar Refractive Surgery with Scanned Intrastromal Picosecond and Femtosecond Laser Pulses in Animal Eyes,” Journal of Refractive Surgery, 14:541-548, Sep./Oct. 1998.
Lee et al., “Thermal Compression and Molding of Atherosclerotic Vascular Tissue With Use of Radiofrequency Energy: Implications for Radiofrequency Balloon Angioplasty,” JACC, American College of Cardiology, 13(5):1167-1175, 1989.
Lima et al., “Efficacy and Safety of Oral Sirolimus to Treat and Prevent In-Stent Restenosis: A Pilot Study Results,” American Heart Association, p. 2929, 2002.
Lima et al., “Systemic Immunosuppression Inhibits In-Stent Coronary Intimal Proliferation in Renal Transplant Patients,” American Heart Association, p. 2928, 2002.
Morice et al., “A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization,” The New England Journal of Medicine, 346(23):1773-1780, Jun. 6, 2002.
Muller-Leisse et al., “Effectiveness and Safety of Ultrasonic Atherosclerotic Plaque Ablation: In Vitro Investigation,” CardioVascular and Interventional Radiology, 16:303-307, 1993.
Nair et al., “Regularized Autoregressive Analysis of Intravascular Ultrasound Backscatter: Improvement in Spatial Accuracy of Tissue Maps,” IEEE Transactions on Ultrasonics, 51(4):420-431, Apr. 2004.
Popma et al., “Percutaneous Coronary and Valvular Intervention,” Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th edition, p. 1364-1405, 2005.
Resar et al., “Endoluminal Sealing of Vascular Wall Disruptions With Radiofrequency-Heated Balloon Angioplasty,” Catheterization and Cardiovascular Diagnosis, 29:161-167, 1993.
Romer et al., “Histopathology of Human Coronary Atherosclerosis by Quantifying Its Chemical Composition With Raman Spectroscopy,” Circulation, 97:878-885, 1998.
Schauerte et al., “Catheter Ablation of Cardiac Autonomic Nerves for Prevention of Vagal Atrial Fibrillation,” Circulation, 102:2774-2780, 2000.
Scheller et al., “Intracoronary Paclitaxel Added to Contrast Media Inhibits In-Stent Restenosis of Porcine Coronary Arteries,” American Heart Association, p. 2227, 2002.
Scheller et al., “Potential solutions to the current problem: coated balloon,” EuroIntervention, 4(Supplement C): C63-C66, 2008.
Shaffer, “Scientific basis of laser energy,” Clinics in Sports Medicine, 21:585-598, 2002.
Shmatukha et al., “MRI temperature mapping during thermal balloon angioplasty,” Physics in Medicine and Biology, 51:N163-N171, 2006.
Slager et al., “Vaporization of Atherosclerotic Plaques by Spark Erosion,” J Am Coll Cardiol, p. 21-25, 1985.
Stiles et al., “Simulated Characterization of Atherosclerotic Lesions in the Coronary Arteries by Measurement of Bioimpedance,” IEEE Transactions on Biomedical Engineering, 50(7): 916-921, Jul. 2003.
Suselbeck et al., “In vivo intravascular electric impedance spectroscopy using a new catheter with integrated microelectrodes,” Basic Res Cardiol, 100:28-34, 2005.
Suselbeck et al., “Intravascular electric impedance spectroscopy of atherosclerotic lesions using a new impedance catheter system,” Basic Res Cardiol, 100:446-452, 2005.
Tepe et al., “Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg,” The New England Journal of Medicine, 358:689-699, 2008.
“Optical Coherence Tomography: Advantages of OCT,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: Image Gallery Cardiovascular Procedures,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: What is OCT?,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: Why Use OCT?,” LightLab Imaging Technology, printed Sep. 3, 2003.
CardioVascular Technologies Inc., “Heated Balloon Device Technology,” 11 pages, 2008.
Strategic Business Development, Inc., “Thermal and Disruptive Angioplasty: A Physician's Guide,” 8 pages, 1990.
Zhang et al., “Non-contact Radio-Frequency Ablation for Obtaining Deeper Lesions,” IEEE Transaction on Biomedical Engineering, vol. 50(2): 218-223, Feb 2003.
Lazebnik et al., “Tissue Strain Analytics Virtual Touch Tissue Imaging and Qualification,” Siemens Whitepaper, 7 pages, Oct. 2008.
Han et al., “Third-Generation Cryosurgery for Primary and Recurrent Prostate Caner,” BJU International, vol. 93: 14-18, 2004.
Zhou et al., “Mechanism Research of Cryoanalgesia,” Neurological Research, Forefront Publishing Group, 17: 307-311, Aug. 1995.
Florete, “Cryoblative Procedure for Back Pain,” Jacksonville Medicine, Oct. 1998, 10 pages, printed Dec. 2009.
Stevenson, “Irrigated RF Ablation: Power Titration and Fluid Management for Optimal Safety Efficacy,” 4 pages, 2005.
Giliatt et al., “The Cause of Nerve Damage in Acute Compression,” Trans Am Neurol Assoc, 99: 71-4, 1974.
Omura et al., “A Mild Acute Compression Induces Neurapraxia in Rat Sciatic Nerve,” The International Journal of Neuroscience, vol. 114 (12):1561-1572, Dec. 2004.
Baun, “Interaction with Soft Tissue,” Principles of General & Vascular Sonography, Chapter 2, pp. 23-24, Before Mar. 2012.
Blue Cross Blue Shield Medical Policy, “Surgery Section—MRI-Guided Focused Ultrasound (MRgFUS) for the Treatment of Uterine Fibroids and Other Tumors,” 5 pages, printed Oct. 19, 2009.
Gentry et al., “Combines 3D Intracardiac Echo and Ultrasound Ablation,” Medical Imaging 2003: Ultrasonic and Signal Processing, 5035:166-173, 2003.
Lafon et al., “Optmizing the Shape of Ultrasound Transducers for Interstitial Thermal Ablations,” MEd Phys. Mar. 2002; 29(3): 290-7 (abstract only), Mar. 2002.
G. Ter Haar, “Ultrasound Focal Beam Surgery,” Ultrasound in Med. & Biol., 1995, 21(9): 1089-1100.
Seip et al., “Transurethral High Intensity Focused Ultrasound: Catheter Based Prototypes and Experimental Results,” IEEE Ultrasonics Symposium Proceeding, 2000, 4 pages.
Toytman et al., “Tissue Dissection with Ultrafast Laser Using Extended and Multiple Foci,” SPIE Proceeding, Optical Interactions with Tissues and Cells XXI, 7562:1-10, 2010.
Zhou et al., “Non-Thermal Ablation of Rabbit Liver VX2 Tumore by Pulsed High Intensity Focused Ultrasound Contrast Agent: Pathological Characteristics,” World Journal of Gastroenterology, 14(43): 6743-6747, Nov. 21, 2008.
Related Publications (1)
Number Date Country
20150150626 A1 Jun 2015 US